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ABSTRACT 
 
LAURA ANTONIETTA DIMICHELE: Focal Adhesion Kinase in Cardiac Development 
and Disease 
(Under the direction of Joan M. Taylor) 
 
 
 
 
In the United States, nearly 80 million adults are affected by cardiovascular 
disease. The spectrum of disease range from congenital structural defects to 
acquired structural changes in response to an increased hemodynamic load on the 
heart, myocardial infarction, or hormonal imbalance. Cardiovascular disease 
accounts for significant amounts of morbidity and mortality and is currently the 
number one cause of death in the U.S.  
Congenital heart disease is the most common cause of infant death from birth 
defects. Genetic studies in lower vertebrates have been critical to the understanding 
of the specific factors required for heart development. These studies suggest that 
cardiac abnormalities may be mediated by abnormal regulation of transcription 
factors. Although several transcription factors involved in cardiac development have 
been elucidated, much regarding specific signaling pathways implicated in abnormal 
cardiogenesis is still unknown.    
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Acquired cardiac disease can occur in response to various stimuli. For 
example, an increased hemodynamic load can result in compensatory hypertrophic 
remodeling and may progress to pathologic hypertrophy.  A common manifestation 
of this pathologic process is a constellation of symptoms known as congestive heart 
failure. 
Focal Adhesion Kinase (FAK) is responsible for a variety of biological 
functions including cell adhesion, migration, proliferation, and survival.  Several 
studies demonstrated a role for FAK binding partners and/or for upstream activators 
of FAK throughout cardiac development and disease.  However, since germline 
deletion of FAK results in early embryonic lethality, it is difficult to study the specific 
role for FAK in cardiac development and disease.  Therefore, we addressed this 
issue by creating several mouse models which express tissue specific expression of 
FAK, or its dominant negative FAK-related non-kinase (FRNK). We used these mice 
to investigate the role of FAK in cardiogenesis, anabolic growth, and cardiac 
disease. Collectively, these conditional mouse models demonstrated that FAK 
activity and/or its expression is required for cardiomyocyte proliferation throughout 
development, is dispensable for anabolic growth of the heart, and is necessary and 
sufficient for the induction of cardiac hypertrophy.  Further characterization of the 
precise signaling pathways downstream of FAK may lead to targets for future 
therapeutic intervention to treat congenital and acquired heart disease.  
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Chapter I 
GENERAL INTRODUCTION 
In this thesis, I describe my work highlighting the importance of focal 
adhesion kinase (FAK) in cardiac development and disease.  Specifically Chapter II 
investigates the role of FAK in the progression of cardiac hypertrophy. In this chapter 
I demonstrated that deletion of FAK protein attenuates the hypertrophic response 
following aortic constriction. Chapter III explores the possibility that FAK activity is 
both required and sufficient for the induction of cardiac hypertrophy. In this chapter I 
utilized two distinct mouse models, one which expresses FRNK specifically in the 
myocardium which we have used to examine whether inhibition of FAK activity will 
block the pressure-overload induced hypertrophic response,  and a second novel 
mouse model which expresses constitutively active FAK in the heart. Lastly, Chapter 
IV describes a mouse model in which cardiac restricted overexpression of the 
dominant negative of FAK, FAK-related non-kinase (FRNK) is induced in the heart 
field in mid-gestation and leads to embryonic lethality between day 14-15 secondary 
to a significant proliferation defect.  I begin with a general introduction on  congenital 
and acquired cardiac diseases, then discuss integrin signaling and the importance of 
FAK signaling in a variety of biological processes, followed by general introductions 
regarding development and cardiac disease then finally respectively discuss the 
specific involvement of FAK in these processes.  
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A. Congenital and Acquired Cardiac Defects 
 Human heart development initiates at 20 days post-conception with the 
formation of the cardiogenic plate and continues until a four-chambered heart is 
formed, thirty days later. In mice, the equivalent process is completed in 6 days.  
During this period of organogenesis, there are ample occasions for defects to occur. 
In fact, congenital heart disease affects close to 1% of human newborns and is the 
most frequent form of major birth defect [1].  These birth defects can manifest in 
many variants. The most common congenital defect is the ventricular septal defect 
which acts as a left to right shunt, allowing oxygen rich blood to flow into the right 
ventricle instead of moving into the aorta. Others defects include atrial septal 
defects, pulmonary and aortic stenosis, and transposition of the great arteries in 
addition to patent ductus arteriosus, which misdirects blood into the lungs due to the 
failure of this temporary vessel to close. Combinations of these defects are observed 
in both DiGeorge Syndrome and Tetralogy of Fallot which consists of the 
combination of four defects, ventricular septal defect, pulmonary valve stenosis, 
misplaced aorta, and ventricular hypertrophy. These disorders represent a 
proportion of commonly recognized congenital cardiac developmental defects that 
commonly affect cardiac function.   
Cardiac morphogenesis is complete upon birth and normal heart growth 
occurs by an anabolic mechanism that involves increased cardiac cell size. 
However, the adult heart can remodel in response to a number of factors that can 
eventually lead to cardiac diseases.  Many stimuli such as an increased 
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hemodynamic load on the heart, myocardial infarction, or hormonal imbalance will 
place strain on the heart and cause it to develop compensatory hypertrophy. Over 
time, the initial response leads to chronic pathological hypertrophy characterized by 
increased left ventricle thickness, amplified myofibrillar protein content, and an 
altered pattern of cardiac gene expression. The resultant clinical outcome is 
congestive heart failure, a syndrome with significant morbidity and mortality that 
afflicts nearly 5 million Americans today.  
On a cellular level, the interaction of cardiomyocytes with their extracellular 
environment is essential for normal physiological formation of the heart. In addition, 
these interactions provide the structural, chemical, and mechanical substrate 
necessary to sustain adequate function of the adult heart [2].  Understanding the 
specific signaling pathways involved between the extracellular environment and 
intracellular proteins is integral in the discoveries of targeted therapies for both 
congenital heart defects and acquired cardiac diseases.  
B. Integrin Signaling 
The extracellular matrix interacts with a family of cell surface receptors 
referred to as integrins. This interaction activates a number of downstream cellular 
signaling pathways important in a variety biological processes [3]. Integrins were 
discovered as proteins that were involved in transmembrane linkage between 
fibronectin and actin and eventually described as an “integrin”  because it was both 
an integral membrane protein and involved in cellular and extracellular matrix (ECM) 
integrity [4, 5]. Integrins are heterodimeric transmembrane receptors composed of 
an α and β subunit [6]. In mammals, integrins comprise a family of 18α and 8β 
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subunits which can form into 24 known combinations of α/β heterodimers.  The 
combination of the specific α and β subunits direct the ligand specificity of the 
integrin complex [7].   
Within this large family of integrins, a smaller number of α and β chains are 
specific to the heart. In cardiomyocytes, six distinct α subunits (α1,α3,α5,α6,α7, and 
α10) are expressed only with the β1 subunit, including a splice variant of β1,termed 
β1D, which is the isoform primarily expressed in the postnatal heart [8, 9]. Some 
integrins, including α1 and α5, are temporally regulated, being expressed in the 
embryonic heart then downregulated postnatally and upregulated following aortic 
constriction, an experimental model of pressure-overload [2].  Upon ligand binding, 
integrins cluster into focal contacts which also contain specific cytoskeleton proteins 
such as talin, vinculin, α-actinin, and actin [10]. In addition to their function as 
structural links between the ECM and cytoskeleton, integrins regulate a variety of 
downstream biological pathways [11].  
 
1. FAK, a Coordinator of Integrin Signaling 
FAK is a key protein involved in integrin signaling. Upon integrin clustering, 
FAK is recruited to sites of cellular contact to the ECM called focal adhesions[7].  
Although integrin ligation is the main activator of FAK, FAK is also activated by 
growth factors, neuropeptides, G-protein coupled receptor agonists, and mechanical 
stimuli [12]. FAK contains an N-terminal domain, a C-terminal focal adhesion 
targeting domain, and a central kinase domain (Figure 1.1). The N-terminus of FAK 
resembles a protein domain termed a FERM domain named for its presence of four 
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proteins; (erythrocyte band four 1-ezrin-radixin-moesin) which interacts with 
transmembrane receptors and with plasma membrane lipids [13]. The amino 
terminus of FAK interacts with several proteins including the tail of β1-containing 
integrins, activated platelet derived growth factor (PDGF) and epidermal growth 
factor (EGF) receptors, the tyrosine kinase Etk, and FERM domain-containing 
protein ezrin; each of which could be involved in regulating FAK’s activity [13]. The 
C-terminus of FAK is rich in protein-protein interaction sites and contains a focal 
adhesion targeting site (FAT) that directs FAK to sites of focal adhesions which is 
essential for its function [14]. The FAT domain contains binding sites for two focal 
adhesion-associated proteins, paxillin and talin. FAK binds to paxillin’s leucine rich 
sequences referred to as LD motifs. These motifs function in protein-protein 
interactions. Paxillin also binds directly to the cytoplasmic domain of integrin α 
subunits as well as vinculin, a focal adhesion protein. Therefore, it has been 
postulated that paxillin may act as a docking partner for FAK at focal adhesions, 
although FAK recruitment to focal adhesions is not completely dependent on binding 
to paxillin [15].  
 As described briefly above, integrin clustering is a major activator of FAK, 
resulting in rapid auto-phosphorylation.  The major site of tyrosine auto-
phosphorylation is tyrosine 397 which correlates with increased catalytic activity. 
This phospho-tyrosine  acts as a docking site for the SH2 domain for the Src family 
of tyrosine kinases as well as other SH2 containing proteins, which include  
phosphotidylinositol 3 kinase (PI3K), phospholipase Cγ (PLCγ), and the adapter 
protein Grb7 [16].  In addition, this Y397-dependent activation of FAK leads to the 
 6
tyrosine phosphorylation of FAK-binding proteins p130Cas and paxillin [17]. FAK 
contains five other sites of tyrosine phosphorylation that are likely phosphorylated by 
bound Src kinases [18]. Phosphorylation of Y576 and Y577 are important for 
maximal catalytic activity and signaling to downstream effectors [18].  
Phosphorylation of tyrosine 925 creates a binding site for the SH2 domain of Grb2 
[19].  Grb2 is an adaptor molecule that connects FAK to the MAP kinase signaling 
pathway by binding to Sos, a GEF (guanine nucleotide exchange factor) for Ras. In 
addition, FAK catalyzed phosphorylation of p130Cas (p130 Crk-associated 
substrate) and/or paxillin can lead to Ras activation by the adaptor molecule Crk. 
The activation of FAK and subsequent activation of downstream effectors are 
responsible for a variety of biological functions. Through signaling pathways 
involving PI3K, PLCγ, MAP kinase, paxillin and p130Cas, FAK has a role in cell 
adhesion, migration, proliferation, and survival. In addition, FAK regulates the 
turnover of focal adhesions by modulating Rho activity. This process may involve the 
FAK binding partner GRAF, a negative inhibitor of Rho [20].  As noted earlier, 
autophosphorylation of FAK leads to activation of the p130Cas pathway as well as 
PI3K.  Experiments using a FAK mutant defective for p130Cas binding failed to 
induce p130Cas phosphorylation and attenuated cell migration [21]. Additional 
studies also showed that a FAK mutant that did not to associate with PI3K also failed 
to stimulate motility in vitro [22].  There is also evidence that suggests that FAK may 
function to regulate cell proliferation by controlling the levels of cyclinD through 
increased transcription of the cyclin D gene by enhancing the binding of an Ets 
transcription factor to the cyclin D promoter [23]. Lastly, in some cell types, FAK has 
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been implicated to increase cell survival. Studies have shown that in response to a 
variety of stimuli, inhibition of FAK can induce apoptosis while overexpression can 
prevent apoptosis [12].  The mechanism for FAK-dependent cell survival is not 
completely understood, but it may involve the association of FAK with PI3K and 
activation of AKT, as well as through Grb2 interaction with the Ras/MAPK pathway 
[24, 25].   
In wildtype embryos, FAK expression gradually increases from E8.0 onward 
and is ubiquitously expressed, though expression is most predominant in the 
mesoderm at midgestation (E8.5) [26]. Consistent with FAK’s critical biological 
functions in vitro, the germline deletion of FAK results in embryonic lethality around 
E8.5. The FAK deficient embryos exhibit a general mesodermal deficiency similar to 
that of the fibronectin (FN) null mouse. Closer examination revealed an absent 
notochord, defects in the fusion of the cardiac plates, and poor vascularization of the 
embryo and yolk sac [26]. Overall, in the absence of FAK, the embryos display 
defects in cell proliferation and/or differentiation, as well as cell migration.  
2. Models of conditional FAK deletion 
Initially experiments performed on cultured fibroblasts derived from the fak-/- 
embryos revealed that depletion of FAK led to reduced motility and increased 
apoptosis [27, 28].  However, recent data using Cre/loxP technology has elucidated 
cell type specific functions of FAK.  Studies from the Reichart lab explored the role of 
FAK in the nervous system. They developed a floxed FAK mouse which was 
crossed with the emx1 promoter which is active in neuroepithelial precursors of 
neurons and glia in the developing cortex and hippocampus beginning at embryonic 
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day 9 [29]. Interestingly, FAK deletion in either radial glia or meningeal fibroblasts 
resulted in aberrant neuronal migration, but the FAK deletion in neurons alone did 
not result in a migration defect [29].  However, FAK depletion led to disrupted 
laminin organization and overall basement membrane assembly and/or remodeling, 
indicating that FAK was likely activating in a non-cell autonomous effect to modify 
neuronal migration.  
Using a similar floxed FAK mouse with an endothelial cell specific Tie2-Cre, 
Jun-Lin Guan’s group discovered that endothelial cell specific deletion of FAK leads 
to embryonic lethality. The embryos were able to develop normally through early 
embryogenesis. However, in late embryogenesis (E13.5) the FAK depleted 
endothelial cells exhibited proliferation and migration abnormalities manifesting in 
defective angiogenesis that was evident in the embryos, yolk sac, and placenta. The  
embryos also exhibited vascular defects and associated edema [30]. There was 
conflicting data published shortly after Jun-Lin Guan’s group which showed 
embryonic lethality at an earlier stage, between E10.5 and 11.5, using the Tie2-cre 
crossed to a different floxed FAK mouse. These endothelial cells (EC) derived from 
the mutant embryos revealed no apparent decrease in proliferation or migration, but 
instead the ECs had aberrant lamellipodial extensions, altered actin cytoskeleton, 
and nonpolarized cell movement [31]. Additionally this work demonstrated that FAK 
played a cell-autonomous function in ECs and that it is crucial for vascular 
development [31]. The different phenotypes in these two models may be due to the 
specific timing of FAK deletion using the two different floxed mice and highlight the 
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possibility that FAK can have different functions throughout the various stages of 
development.  
 Recently we published data using the floxed FAK mice developed by the 
Reichart lab, showing that FAK deletion from Nkx2.5-Cre expressing cells in the 
primary and secondary heart field resulted in lethality shortly after birth. These mice 
had a profound sub-aortic ventricular septal defect and associated mal-alignment of 
the outflow tract due to a specific cardiomyocyte migration defect in the absence of 
any noted proliferation or cell survival defects [32].  
My work described in Chapter II utilized the Mlc2v-Cre line to induce a 
cardiomyocyte-specific deletion in the adult myocardium. In this model, conditional 
deletion of FAK from the myocardium of adult mice did not affect basal cardiac 
performance, myocyte viability, or myofibrillar architecture. However, deletion of FAK 
attenuated the increase in left ventricular posterior wall thickness, myocyte cross-
sectional area and hypertrophy-associated atrial natriuretic factor induction following 
pressure overload in the absence of apoptosis [33].  These data highlight a 
necessary role for FAK in pathological remodeling and suggests a role for FAK as 
the mechanotransducer for biomechanical stress in the heart.  
3. Proline Rich Tyrosine Kinase 2 (Pyk2) 
A protein that shares approximately 48% amino acid identity (65% similarity) 
with FAK is Pyk2 (proline rich tyrosine kinase 2).  Both proteins share similar 
domains and both have been identified in human, mouse, chicken, and frog[34]. 
Unlike FAK’s ubiquitous expression, Pyk2 is highly expressed in the central nervous 
system and in cells from hematopoietic origin. A number of FAK’s binding partners 
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also bind Pyk2, including Src family kinases and paxillin. Unlike FAK, Pyk2 is 
localized to the cytoplasm and concentrated in perinuclear regions and is regulated 
by stimuli that elevate cytoplasmic levels of calcium [12]. Studies in FAK-deficient 
fibroblasts showed Pyk2 localization at sites of focal adhesions and integrin induced 
phosphorylation of Pyk2, suggesting that Pyk2 may compensate for loss of FAK in 
some circumstances to mediate signal transduction [35]. Although these two 
molecules are very similar in structure, studies have shown that over-expression of 
Pyk2, but not FAK, in rat and mouse fibroblasts leads to apoptotic cell death [35].  
Lastly, the Pyk2 null mice, unlike FAK null mice, are viable and fertile without any 
overt developmental phenotype with the exception of a macrophage migration and 
function defect [36]. Throughout our studies we have taken measures to determine 
whether Pyk2 may function to compensate or even exacerbate the phenotypes 
observed in our conditional FAK knock-out mice. 
4. FAK-Related Non-Kinase (FRNK) 
FAK-related non-kinase or FRNK is a 43 kDa version of FAK comprised of the 
C-terminus of FAK, but lacking the kinase domain (Figure 1.1). Since FRNK is 
comprised of the C-terminus of FAK, it is targeted to focal adhesions and binds to 
critical FAK binding partners (p130Cas, paxillin, talin, GRAF). FRNK is transcribed 
from an alternative promoter located in the intron of the FAK gene. Unlike FAK, 
FRNK is expressed primarily in the vasculature smooth muscle and is upregulated 
following vascular injury [37]. Interestingly, studies have shown that FRNK can act 
as an inhibitor of integrin dependent FAK activity and downstream signaling. Since 
FAK is activated by homodimer formation and trans-phosphorylation FRNK likely 
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inhibits FAK activity by forming inactive FAK:FRNK heterodimers [12].  FRNK has 
been used as a tool to study the role of FAK in many systems including the 
cardiovascular system.  For example, infection of cultured cardiomyocytes with an 
adenovirus containing GFP-FRNK attenuated phenylepherine (PE)-stimulated 
hypertrophy, determined by cell size, sarcomeric organization, and induction of atrial 
natriuretic factor [37, 38].  Further studies used FRNK to determine its ability to 
inhibit endothelin-1 and stretch mediated hypertrophy [39]. My studies described in 
Chapter III of this thesis describe a mouse model we generated that overexpresses 
FRNK in myocytes shortly after birth. This model has enabled us to examine a role 
for FAK in anabolic growth of the heart and will allow us to determine the different 
roles of FAK as a signaling molecule versus a scaffold for focal adhesion proteins.  
C. Cardiac Development  
The heart is the first organ to form in the embryo and is crucial for embryonic 
viability.  Defects in the carefully orchestrated steps that govern cardiac 
development contribute significantly to fetal and childhood mortality [40].  Congential 
heart abnormalities are the most common birth defect and account for most of the 
deaths from birth defects during the first year of life and their frequency in miscarried 
pregnancies is estimated to be tenfold higher [41, 42].  Although in the past decade, 
much has been elucidated regarding the molecular blueprint underlying cardiac 
morphogenesis, there are many details that remain to be revealed.  Such questions 
are directed at describing how diverse cell fates are specified, the mechanisms that 
connect mutations in specific proteins to cardiac phenotypes, as well as the details 
of the cell-autonomous and non-cell autonomous signaling mechanisms controlling 
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myocyte growth and function [43]. Understanding these mechanisms will hopefully 
provide new therapies targeted at restoring cardiac function in patients afflicted with 
congenital heart disease.    
1. Genetics of Cardiac Development 
Congenital heart defects can occur during the multiple steps involved in 
cardiac development. The first step involves specification of the cardiac precursors 
followed by the migration of these cells and fusion of the heart tube. The second 
step is the formation of cardiac chambers due to a rightward looping of the heart 
tube. Following chamber formation, a series of events leads to the development of 
the myocardial protrusions into the lumen called trabeculations, the construction of 
heart valves, and septation of the chambers. Finally, the development of the 
multilayered spiral system of the ventricles completes the myocardial architecture 
[44].   
The heart forms from two separate progenitor cell populations or heart fields 
referred to as the primary and secondary heart fields. These fields divide from a 
common progenitor at gastrulation [45-47].  The primary heart field arises from the 
anterior splanchnic mesoderm and is responsible for the formation of the cardiac 
crescent and ultimately the left ventricle and atria [48]. The secondary heart field 
arising from the pharyngeal mesoderm contributes to the right ventricle and outflow 
tract [45, 46, 49]. The primary heart field is distinguished by expression of specific 
transcription factors Tbx5, bhHLH and Hand2 whereas the secondary heart field is 
mediated by the transcription factor Isl1 and Fgf10 [45, 46].  The homeobox gene 
Nxk2.5 is expressed in both heart fields [50].  
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Following gastrulation, the mesoderm migrates to form the cardiac crescents. 
At this time, the specification of cardiomyocytes occurs from the anterior lateral 
mesoderm in response to factors excreted from the adjacent ectoderm, including 
bone morphogenic proteins. In vertebrates, the expression of the homeobox gene 
Nkx2.5 is the earliest marker of the cardiac lineage [51].  Soon after specification, 
the cardiac precursor cells migrate anteriorly towards the midline and fuse into a 
single heart tube. This migration is directed by FN within the ECM. The cardiac tube 
contains a distinct myocardial layer of one to two cell layers and an endocardial layer 
separated by an acellular cardiac jelly composed of ECM. Studies have highlighted 
the importance of GATA transcription factors in the formation of the heart tube [52]. 
GATA4 null mice arrested in development between E7.0 and E9.5 due to severe 
abnormalities including an absent primitive heart tube and foregut [52]. At this stage 
the heart tube is divided along the anterior-posterior axis into precursors for the fully 
formed heart and there is the addition of cells from the secondary heart field. This 
heart tube next undergoes a rightward looping to change the anterior/posterior 
polarity of the heart to left/right polarity. This change is necessary to align the 
ventricles with the vasculature and for proper orientation of the pulmonary artery on 
the right and the systemic artery (aorta) on the left [53].  Left-right symmetry is 
guided by the transcription factor Pxt2 which is expressed on the left side of 
developing organs. Solidification of the basal portions of the trabeculae via 
proliferation of the ventricular myocytes involves neuregulin growth factors secreted 
from the endocarduim to their myocardial receptors Erb2 and Erb4 [54].  Other 
endocardial factors such as vascular endothelial growth factor (VEGF) and 
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angiopoetin-1 are involved in ventricular trabeculation [55, 56]. This compaction 
correlates with the invasion of coronary vasculature from the epicardium and also 
occurs around the same time as the formation of cardiac valves. Signaling between 
the endocardial and myocardial cells in the endocardial cushions involves TGFβ and 
induces the transformation of endocardial cells into mesenchymal cells which then 
migrate into the cushions to form the fibrous tissue of the valves [57].  In addition, 
studies have revealed the transcription factors, NF-ATc and Smad6 are important in 
the formation of cardiac valves [58, 59].  Although these genes represent a basic 
plan for development, further discovery of the genetic complexity involved in cardiac 
development is critical not only for the understanding of congenital defects but also 
for treatment of adult acquired cardiac diseases.  
2. FAK and FAK-Related Proteins in Cardiac Development 
As noted above, the germline deletion of FAK is embryonic lethal between 
E8.5 and E10. The mesodermal defect resulting from the loss of FAK indicates that 
FAK may be important in cardiac development. In support of this hypothesis, the 
major activator of FAK (FN), as well as several FAK binding partners of have been 
implicated in heart development.   
The major extrinsic activator of FAK signaling is the ECM protein, FN.  A 
study involving a model that inactivates both FN alleles causes embryonic lethality at 
E8.5, highlights the importance of FN in development [60].  Development of FN-/- 
embryos proceeds normally through implantation and gastrulation, however as the 
embryo progresses it displays fundamental defects in mesodermal migration, 
adhesion, proliferation, or differentiation. Specifically, these mouse embryos display 
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abnormal vasculature and a structurally deformed heart. In the more severe  
phenotypes, the loss of FN resulted in a lack of fusion of the heart primordia. In less 
severe models, the heart contained thickened myocardial tissue, a defect in cardiac 
jelly, and abnormal endothelium [61].  Overall, FN is critical for embryonic 
development of the embryo as well as for cardiac development. 
Mice that have been engineered to delete p130Cas, an adaptor molecule that 
is phosphorylated by FAK and is important in cell migration and proliferation, result 
in an embryonic lethal phenotype at embryonic day 12.5.  These embryos exhibit 
marked growth retardation and overall systemic congestion compared to controls.  
The p130Cas null hearts were poorly formed and contained myofibrillar 
disorganization and disruption of the Z-disks [62].  This data provides evidence that 
alterations in the FAK signaling cascade can lead to defective sarcomeric 
organization and impaired cardiac development.  
Another FAK binding protein essential for heart development is paxillin. 
Paxillin is phosphorylated following integrin activation and serves as a scaffold to 
mediate downstream integrin signals. Germline deletion of paxillin results in a similar 
phenotype as the deletion of FN [63]. In both models, there are defects in the 
development of mesoderm derived structures including the heart. In ex vivo 
experiments, paxillin-/- cells show deficient focal adhesion formation, migration, and 
localization of FAK to focal adhesions. Because of this similarity with the FN-/- 
mouse, paxillin is thought to be a critical transducer of FN signals in development 
[63].   
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Given that the FAK germline deletion leads to profound mesodermal defect 
and due to the variety of FAK binding proteins that are involved in cardiac 
development, it seems to follow that FAK regulates critical pathways that are 
necessary for normal cardiac development and function.  Elucidating these 
pathways may provide insight into the signaling mechanisms underlying several 
congenital heart abnormalities and may ultimately result in new targeted small-
molecule therapeutics. 
D. Cardiac Disease  
 Currently, approximately 5 million Americans are afflicted with congestive 
heart failure (CHF), with 550,000 cases diagnosed in the United States each year 
[64]. This emerging epidemic is  caused by  a complex combination of structural, 
functional, and biological alterations [65]. The induction of CHF associated with 
cardiac hypertrophy is an initial compensatory response to an increased 
hemodynamic load on the heart. These adaptive mechanisms include local and 
systemic release of cytokines, peptides, and neurohormones, that result in increased  
cardiomyocyte size and increased myofibrillar content [66]. However, chronic 
stimulation by pressure or volume overload, myocardial infarction, or hormonal 
imbalance can lead to pathological hypertrophy and eventually congestive heart 
failure, characterized by an altered pattern of cardiac gene expression, fibrosis, re-
expression of fetal gene transcripts and cardiac dysfunction [67, 68].  Despite the 
recent advances in the study of heart disease and the understanding of cardiac 
function at genetic and molecular levels, cardiovascular disease is still the number 
one cause of death in the western world [1].  It therefore stands that continued 
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investigation into the signaling pathways governing normal and abnormal cardiac 
growth, apoptosis and survival is key to the process of developing novel therapies 
for treatment of CHF [43].  
1. Gene Mutations in Human Cardiomyopathies 
In response to constant pathological stress the heart undergoes ventricular 
remodeling. This remodeling can manifest as one of two distinct pathologies, 
hypertrophic cardiomyopathy (HCM) involving increased wall thickness without 
chamber expansion or dilated cardiomyopathy (DCM) associated with normal or 
increased wall thickness and enlarged chamber size [69]. Physiologically, these 
phenotypic changes result in impaired diastolic relaxation in HCM and impaired 
systolic function in DCM [70]. Histologically, HCM is characterized by enlarged, 
disorganized myocytes that die prematurely and subsequently result in increased 
fibrosis. While DCM also demonstrates degenerating myocytes and increased 
fibrosis,  it is notably characterized by lack of myocyte disarray [69].  The incidence 
of sudden cardiac death in HCM is 2-4% in adults and current treatment involving β-
blockers, calcium channel antagonists, and antiarrhythmic drugs appear to be 
promising treatments [71].  However, despite advancements in therapy, the average 
five year survival rate for DCM patients who do not undergo cardiac transplant is 
less than 50% [71].  
Studies detailing cases of familial hypertrophic cardiomyopathy reveal that 
mutations in genes encoding structural sarcomeric proteins are implicated in the 
disease [72, 73].  Heart cells generate contractile force by the sarcomere and 
transmit this force to the ECM [69]. The proteins located at the Z disks of 
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sarcomeres sense the stretch on the cell and transduce signals that are necessary 
for cardiomyocyte contraction.  Genetic studies of familial hypertrophic 
cardiomyopathy  have identified several genetic mutations in sarcomeric proteins 
that include the β myosin heavy chain (βMHC), myosin binding protein C (MyBP-C), 
cardiac troponin T (TnT) and cardiac troponin I (TnI), tropomyosin(Tm), myosin light 
chain, actin, and titin (Figure 1.2) [74, 75].  Actin is the major component of the thin 
filament and forms a complex with Tm and troponins, contributing to the contractile 
unit of heart muscle. Part of the thick filament is made of βMHC. βMHC contains a 
head region that binds actin and ATP and is essential for generation of movement 
needed for contraction [76]. The S2 subfragment of βMHC binds to the head region 
of βMHC and connects to MyBP-C and titin, assembling the thick fragment and 
stabilizing the protein [76].  Mutations in actin, Tm, βMHC, TnT, TnI, MyBP-C, and 
titin, can lead to DCM however the sites mutated in these proteins differ than the 
mutations linked to HCM [69]. Mutations in sarcomeric proteins observed in patients 
with HCM characteristically result in increased actin-activated ATPase activity as 
well as greater force production and faster actin-filament sliding whereas mutations 
observed in DCM result in impaired force transmission.   
Although some mutations in sarcomeric genes are linked to DCM, the 
majority of DCM patients have mutations in cytoskeletal proteins [72, 73]. Alterations 
in desmin, dystrophin, metavinculin, muscle LIM protein (MLP), α-actinin, and ZASP 
have all been linked to DCM [77].  Desmin is a cytoskeletal protein that is involved in 
intermediate filament organization and is responsible for connecting the nuclear and 
plasma membranes, thereby stabilizing the sarcomere [78].  Dystrophin, a large 
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cytoskeletal protein, interacts with actin and is thought to play a role in force 
transduction [79]. Located in the intercalated disks, metavinculin, an isoform of 
vinculin, anchors thin filaments and is involved in force transmission [80].  Interacting 
with both titin and α-actinin, a protein involved in anchoring myofibrillar actin 
filaments, MLP is implicated in muscle differentiation and sarcomere assembly [78]. 
Lastly, ZASP plays an important role bridging the sarcomere to the cytoskeletal 
network. Despite their varied functions, mutations in these genes result in a DCM 
phenotype.  
It follows that the above discussed proteins provide structural functions and 
therefore must work in concert with a signaling molecule that is able to sense the 
stretch applied to the cell.  FAK, although yet to be implicated in human 
cardiomyopathies, connects the sarcomeric proteins to the ECM and may be 
responsible for transmitting signals activated in myocyte stretch and contraction. As 
stated above, FAK is activated following integrin ligation and FAK drives the 
formation of a focal adhesion complex that involves many of the aforementioned 
proteins that may play a role in human cardiomyopathies.  Therefore it is possible 
that FAK is acting as an effector for the mechanosensors in the cell (the integrins), 
and impaired FAK signaling could affect the subsequent downstream proteins 
involved in both HCM and DCM (Figure 1.3). Studies discussed in Chapter II of this 
thesis suggest that if FAK is absent from the focal adhesion complex, which is 
known to link Z disk proteins to the ECM and for force transmission, a DCM 
phenotype occurs following aortic constriction. In addition, I discuss a novel mouse 
model in Chapter III which ectopically expresses FRNK in the myocardium. In this 
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model the absence of FAK activity is dispensable for anabolic growth but abrogates 
the hypertrophic progression following aortic constriction. These data indicate that 
FAK activity is essential for this process. Furthermore, I also introduce a novel, 
cardiac specific FAK overexpression model that results in hypertrophic remodeling of 
the myocardium (Figure 1.3). In summary, our findings support a model whereby 
FAK activity is central to the signaling complex between the ECM and Z-disk 
proteins.  
2. Signaling Mechanisms Involved in Cardiac Hypertrophy 
Varieties of cellular receptors are stimulated during cardiac hypertrophy and 
lead to different responses. Generally, the activation of receptor tyrosine kinases 
(IGF-1) initiates a physiological hypertrophy phenotype where as activation of the G 
protein coupled receptors (GPCR) stimulates a pathological hypertrophy response.  
Both physiological hypertrophy and pathological hypertrophy have the same initial 
compensatory response. In physiological hypertrophy, increased exercise leads to 
compensatory cell growth, which is beneficial to the heart over time. However, in 
pathological hypertrophy, the initial compensatory growth is followed by detrimental 
reversion to the fetal gene profile, and increased fibrosis, culminating in heart failure 
and an eventual increase in morbidity and mortality.  Although many molecules have 
been defined to have a specific role in either pathological or physiological 
hypertrophy, the further delineation of the distinct signaling pathways is critical for 
the treatment of heart disease (Figure 1.4). From here on, unless specified, cardiac 
hypertrophy refers to the pathological response.  
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Normal anabolic cardiac growth and physiological hypertrophy are largely 
mediated through insulin growth factor-1 (IGF-1) and growth hormone (GH).  GH is 
activated via increased production of IGF-1. IGF-1 signals through its membrane 
tyrosine kinase receptor (orange in Figure 1.4), activating the PI3K subunit 
α (p110α). This event activates downstream effectors such as the Ser/Thr kinase 
AKT and its activator 3-phosphoinositide-dependent protein kinase-1 (PDK-1) [81-
83].  
 The major signaling pathway implicated in physiological hypertrophy involves 
PI3K, a protein implicated in various cellular processes including proliferation, 
survival, and cytoskeleton organization [84-87]. PI3K is part of a group of lipid 
kinases which are activated by receptor tyrosine kinases such as IGF-1 and GPCRs 
to regulate various cellular functions, including cell growth and survival [83].  In vivo 
data have shown that mice expressing a constitutively active form of PI3K in 
myocytes develop increased myocyte cell size and increased cardiac contractility 
with no evidence of pathological hypertrophy, implicating a crucial role for PI3K in 
the regulation of cardiac cell growth [85, 87]. In addition, loss of kinase activity of the 
α- and γ- subunits of PI3K leads to different effects. Mice expressing a cardiac 
specific dominant negative of p110α show that p110α is required for the induction of 
physiological hypertrophy but is not necessary for the hypertrophic response to 
pressure overload.  In addition, data from  mice carrying a targeted mutation in the 
PI3Kγ gene show that the p110γ is required for stress induced hypertrophy but not 
normal growth [87-89]. The downstream effector, AKT, is required for normal heart 
growth as suggested by data from AKT null mice [90].  In fact, AKT null mice have 
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defects in both fetal and postnatal growth. There defects continue into adulthood 
[90].  Downstream targets of AKT include the mammalian target of rapamycin 
(mTOR), and glycogen synthase kinase 3β (GSK3β).  The serine/threonine protein 
kinase mTOR mediates protein synthesis and transcription necessary for 
hypertrophy [91-93]. GSK3β is a serine/threonine protein kinase that is catalytically 
active even under unstimulated conditions [94].  When stimulated by IGF-1 signaling 
through the PI3K-AKT pathway, GSK3β  is phosphorylated and becomes a negative 
regulator of cardiac pathological hypertrophy by inhibiting increases in the rate of 
protein synthesis and hypertrophic gene expression [95, 96].  
In addition to IGF signaling, PKCε,  a molecule thought to be specific to 
physiological hypertrophy, is activated by mechanical stress, GPCR, and 
physiological hypertrophic stimuli [97, 98].   
 GPCRs (green in Figure 1.4) are activated by hormones or neurotransmitters  
[99]. The G protein Gq is thought to be important in the induction of cardiac 
hypertrophy because ligands such as phenylepherine, angiotensin II (AngII) and 
endothelin I activate Gq-coupled receptors and trigger in vitro induction of 
cardiomyocyte hypertrophy [100-102]. In vivo studies have also implicated a role for 
GPCR in pressure overload ventricular hypertrophy [103]. These studies utilize 
transgenic mice that display an overexpression of either Gαq, α1-adrenergic 
receptors (ARs) or AngII receptors and all develop cardiac hypertrophy [104-106].  
Progression of hypertrophy is accompanied by an increased accumulation of ECM 
proteins, such as FN [107].  Many studies have noted an intimate relationship 
between cardiac hypertrophy and modifications in the ECM as reviewed by Bendall 
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et. al. [108]. As noted above, integrins (red in Figure 1.4) mediate interactions 
between the cell membrane and the ECM, which results in the formation of transient 
signaling complexes termed focal adhesions. Interestingly, the α5β1 integrin (which is 
the major FN receptor) has been shown to be upregulated during the progression of 
cardiac hypertrophy [109].  Studies have shown that blocking β-1 integrin effectively 
blocks hypertrophy and that overexpression of activated α5 integrin stimulates 
hypertrophy [110, 111]. Therefore, signaling via integrins (red) and GPCR (green) 
are both associated with hypertrophy (Figure 1.4).  Downstream signals from each of 
these receptor groups have also been shown to be upregulated or activated 
following the induction of cardiac hypertrophy such as mitogen-activated protein 
kinase (MAPK) family members, (specifically extracellular–regulated kinases 
(ERK1/2) [112] and p38 MAPK [113])  as well as protein kinase C [114], Rho [115] 
and FAK [116]. Therefore, these data indicate that signaling through GPCR mainly 
activates a pathological response whereas signaling through the tyrosine kinases is 
able to induce a physiological hypertrophic response.  
3. Downstream Effectors of FAK Involved in Hypertrophy 
 The aggregation of integrins on the cell membrane is the major activator of 
FAK and results in the assembly of a multicomponent signaling complex [117]. In 
addition to integrin clustering, growth factor stimulation by PDGF, [118] and EGF, 
[55]), as well as signaling through some GPCRs by ligands such as PE and 
lysophophatidic acid, also activate FAK [119].  Therefore, FAK is activated by a 
variety of stimuli, including integrin clustering, growth factors, and GPCR, indicating 
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that FAK may be a key molecule in coordinating the downstream signals that 
regulate cell growth (Figure 1.5).  
FAK is known to mediate downstream biological signals involved in 
hypertrophy through FYN, CSK, PI3K, PLC-γ, and MAPK pathways [12, 120]. In fact, 
transgenic models altering these downstream effectors of FAK including PI3K, the 
small GTPases Rac and Rho, ERK, and PKC, induce or attenuate the hypertrophy.  
As stated earlier, PI3K is activated by IGF-1 and plays a crucial role in the 
regulation of cardiac cell growth throughout development and in the progression of 
physiological hypertrophy [85, 87].  Several transgenic mouse models altering the 
PI3K subunits as well as the downstream effector of PI3K, AKT, demonstrate the 
importance of this signaling pathway in the progression of physiological hypertrophy.  
 The small GTPases are a critical signaling link between cell membrane 
receptors and intracellular pathways.  The GTPases are small proteins that bind 
guanosine triphosphate (GTP) and regulate a wide variety of functions in the cell 
including growth, differentiation and migration.  The Rho family of small G proteins 
(Rho, Ras, Cdc42), are involved in cytoskeletal organization of cardiomyocytes 
[121]. RhoA activates RhoKinase (ROCK) which, in turn, activates myosin light chain 
kinase (MLCK). MLCK, which can also be activated by calmodulin is involved in 
sarcomeric organization in vitro [122]. In addition, dominant negative RhoA can 
inhibit PE, ET-1, or Gq stimulated hypertrophy in vitro, while in vivo overexpression 
of RhoA led to cardiac abnormalities that resulted in heart failure [123].  Mice 
containing a constitutively active form of Ras were able to induce cardiac 
hypertrophy and in vitro Ras expression resulted in hypertrophic gene expression. 
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Accordingly, the dominant negative Ras mutant prevented PE-induced hypertrophy 
[124]. 
There are several MAP kinases that likely have a role in cardiac hypertrophy. 
In response to acute pressure overload, ERK1/2 is activated and stimulates 
expression of immediate early genes known to be activated in initial stages of 
hypertrophic growth [125]. Direct evidence implicating ERK1/2 signaling comes from 
studies in which a transgenic mouse containing activated MEK1 (immediate 
upstream activator of ERK1/2) downstream of the cardiac specific αMHC promoter 
was generated. This mouse demonstrated mild concentric hypertrophy and an 
increase in heart weight to body weight ratio, along with increased contractile 
performance. Overall, these studies highlighted that the MEK1/ERK1/2 pathway was 
sufficient to induce a hypertrophic response in vivo[126]. Interestingly, following 
mechanical stress, the adaptor molecule Grb2 is recruited to FAK. Grb2 can activate 
MAPK via interactions with Ras. Mice haploinsufficient for Grb2 inhibit p38MAPK 
and JNK activation following pressure overload and attenuate the hypertrophic 
response[127].  Thus each of these MAP Kinases may play a role in the 
development of cardiac hypertrophy.  
Isoforms of PKC, a ubiquitously expressed serine/threonine kinase, are also 
involved in the progression of cardiac hypertrophy. Multiple studies have shown that 
transgenic expression of PKCβ and ε are likely involved in the progression of cardiac 
hypertrophy. However, only PKCα has been shown to be necessary and sufficient to 
induce hypertrophy in vitro[128].  
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4. FAK’s Role in Cardiac Hypertrophy 
 Although FAK protein levels are low in the adult heart relative to the fetal 
heart, studies have demonstrated that FAK activity is increased in hypertrophic 
hearts [107].  As stated above, past in vitro experiments conducted by our lab 
indicate that ectopic expression of FRNK (inhibition of FAK activity) attenuated PE 
induced cardiomyocyte hypertrophy. Subsequent reports have shown that 
overexpression of FRNK also attenuated endothelin-I and stretch/angiotensin II-
stimulated cardiomyocyte hypertrophy [129, 130]. Knowing that FAK plays a role in 
vitro in the induction of cardiomyocyte hypertrophy, and that many signals both 
downstream and upstream of FAK signaling are involved in the promotion of 
hypertrophy in humans and mice, we hypothesized that FAK is likely an important 
transducer of the hypertrophic signals in the adult heart.  
E. Goals of Thesis 
 In this thesis I explore the role of FAK throughout cardiac development, 
anabolic growth, and in the progression of cardiac disease. To study FAK, we have 
created novel mouse models that allow us to study the effect of decreased FAK 
activity in the developing heart fields as well as the postnatal heart. In addition, we 
have conditionally deleted FAK from the adult myocardium allowing us to study its 
role in the progression of pressure-overload induced hypertrophy. We have also 
generated a mouse model with conditional overexpression of constitutively active 
FAK in the myocardium to see if in the absence of stimuli, increased FAK activity will 
induce cardiac hypertrophy. In Chapter II of this thesis I show that following aortic 
constriction, mice with FAK deleted from the myocardium, fail to undergo 
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compensatory hypertrophy following pressure overload.  Knowing that FAK deletion 
was able to attenuate the hypertrophic response, Chapter III asks whether FAK 
activity is necessary and sufficient for the induction of hypertrophy. In this chapter, I 
show that adult mice that exhibit cardiac specific inhibition of FAK activity from one 
day postnatal onward are phenotypically and physiologically similar to littermate 
controls, but have attenuated hypertrophic response.  This chapter also describes a 
novel transgenic mouse model which expresses a constitutively active form of FAK 
from at least E12.5 onward under the control of a modified βMHC promoter.  Thus 
far, my data suggests that the continual activation of FAK is sufficient to induce 
cardiac hypertrophy. Chapter IV of this thesis describes the investigation of the 
overexpression of FRNK in the heart fields of the developing heart and shows that 
decreased FAK activity at mid-gestation is critical for embryonic viability. Conditional 
overexpression of FRNK resulted in a significant decrease in myocyte proliferation, 
and malformations of the endocardial cushion collectively resulting in ventricular and 
atrial septal defects, as well as defects in valulogenesis. These studies suggest that 
FAK activity is crucial for cardiac morphogenesis. 
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Figure 1.1 Schematic of Focal Adhesion Kinase (FAK) and Focal Adhesion 
Kinase-Related Non-Kinase (FRNK). FAK contains three major domains, an N-
terminal integrin binding domain, a central kinase domain and a C-terminal focal 
adhesion targeting domain (FAT). The major auto-phosphorylation site on FAK is at 
tyrosine 397 which acts as a docking site for the SH2 domain of Src. FRNK is 
transcribed from an alternative promoter located in the intron of the FAK gene and is 
identical to the C-terminus of FAK, but lacks the kinase domain.  
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Figure 1.2 Sarcomeric and Cytoskeletal Proteins Involved in Human 
Cardiomyopathies. Familial hypertrophic cardiomyopathy (HCM) is linked to  
mutations in genes encoding structural sarcomeric proteins. However, dilated 
cardiomyopathy (DCM) is linked to mutations in genes encoding cytoskeletal 
proteins. Both the sarcomeric and cytoskeletal proteins are located at the Z-disk of 
the myofibrills.  
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Figure 1.3 FAK is Central for the Correct Function of Z-disk Proteins.  
Disruptions in sarcomeric proteins lead to HCM. This process is likely mediated by 
malformations in contractility sensed by receptors.  Receptors initiate signaling 
cascade to induce hypertrophy which involved the addition of sarcomeric units. FAK 
may be central to these mechano-induced signals.  
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Figure 1.4. Maladaptive and Physiological Signaling Pathways. FAK is activated 
following a variety of stimuli which act through receptors including GPCRs, integrins, 
and growth factor receptors. Signaling through GPCRs and integrins activated 
downstream effectors involved in maladaptive hypertrophic remodeling, whereas 
signaling through the growth factor receptor IGF-1 stimulates the physiological 
hypertrophic pathway.  
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Figure 1.5 Pathways Involved in Cardiac Hypertrophy. Cardiac hypertrophy can 
be stimulated through various pathways including those stimulated by integrins, 
GPCR, calcium channels ad receptor tyrosine kinases. Interestingly, the pathways 
that induce cardiac hypertrophy also stimulate FAK activity.  
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CHAPTER II 
 
MYOCYTE-RESTRICTED FAK DELETION ATTENUATES PRESSURE-
OVERLOAD INDUCED HYPERTROPHY 
 
A. Introduction 
 
 In the face of chronic pressure or volume overload, the adult heart undergoes 
pathological hypertrophic growth. This response is characterized by an increase in 
cardiomyocyte size and myofibrillar content as well as an altered pattern of cardiac 
gene expression including induction of immediate early genes and re-expression of 
several fetal gene transcripts.  Initially these changes are compensatory, but may 
eventually lead to decreases in cardiac performance and heart failure [128].  The 
precise molecular mechanisms that regulate anabolic or pathologic myocardial 
hypertrophy are not completely known, but studies have implicated a variety of 
neuroendocrine and autocrine factors, many of which act through G-protein coupled 
receptors (in particular those coupled to Gαq) [131].   
 Extensive evidence indicates that extracellular matrix (ECM)/integrin receptor 
signaling is also an important regulator of myocardial hypertrophy.  Upregulation of 
collagen III, fibronectin (FN), osteopontin, or their cognate integrin receptors, β1, α3 
and α5, correlates with the advancement of cardiac hypertrophy in animal models 
[132].  Also transgenic mice that express a myocyte-restricted activated α5 integrin 
develop profound cardiac hypertrophy [133], whereas myocyte-restricted deletion of 
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the β1 integrin in adult mouse hearts leads to a dilated cardiomyopathy and 
concomitant heart failure [60, 134].  In addition, mutations in the structural focal 
adhesion proteins muscle LIM protein and metavinculin are associated with dilated 
cardiomyopathy in patients [80, 135].  Collectively, these studies underscore the 
possibility that defects in integrin signaling may play a direct role in regulating 
cardiomyocyte sarcomere formation and function during cardiac development and 
disease. 
  One of the major proteins involved in the integrin intracellular signaling 
cascade is the non-receptor protein tyrosine kinase, focal adhesion kinase (FAK), 
which is strongly and rapidly activated by various growth factors and by ligation of all 
β1, β3 or β5 containing integrins [136].  Through multiple protein-protein interactions, 
activation of FAK results in the subsequent activation of the ERK and JNK growth 
promoting MAP kinases and the cytoskeletal regulating small molecular weight 
GTPases Rac and Rho, some of the same molecules implicated in myocyte 
hypertrophy [131, 136].    
 Although a direct role for FAK in cardiac growth and development has yet to be 
examined, germline deletion of FAK results in general mesodermal defects and 
embryonic lethality between E7.5-10 (similar to both FN-/-, and α5-/- mice) and fak-/- 
hearts lack separate mesocardial and endocardial layers, indicative of a defect in 
cardiomyocyte maturation [137-139].   Interestingly, recent work by our group and by 
others clearly indicate that FAK is activated in cultured cardiomyocytes by a variety 
of hypertrophic stimuli [140-143] and that increased cardiac FAK activity is induced 
following pressure-overload in vivo [144-147].  The idea that FAK activation may 
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play a direct role in the development of cardiomyocyte hypertrophy is evident from 
our initial findings that the activation of FAK is required for phenylephrine (PE)-
stimulated hypertrophy of cultured cells and similar findings from others that FAK is 
required for maximal endothelin-1 and stretch-induced hypertrophy in vitro [141, 148, 
149].    
To test the possibility that FAK inactivation could prevent cardiac hypertrophy 
in vivo, we generated a mouse model that produces conditional myocyte-specific 
inhibition of FAK activity as well as a model that produces a conditional myocyte-
specific deletion of FAK in the adult heart.  In support of recent findings from Peng 
et. al., we show that inactivation of FAK in the adult myocardium does not affect 
basal cardiac function [150].  However, we show that hearts with myocyte-specific 
FAK depletion or inhibition do not develop concentric hypertrophy upon induction of 
biomechanical stress by transverse aortic constriction (TAC).  These studies show 
that FAK plays a significant role in the development of compensatory hypertrophy in 
the intact myocardium and highlight the possibility that FAK serves to integrate 
growth signals from various hypertrophic stimuli.   
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B. Materials and Methods 
Generation of MFKO Mice.  Drs. Louis Reichardt and Hilary Beggs (UCSF) 
graciously provided the fakflox mice and Dr. Kenneth Chien (Harvard) graciously 
provided the mlc2vCre knock-in mice[29, 151].  All mice were backcrossed to the 
C57black6 background at least 8 generations prior to subsequent breeding.  DNA 
isolated from tail snips or tissues was subjected to PCR analysis using primers 
specific for Cre and the presence of the targeted or recombined FAK allele as 
described previously [29, 151].  Mice were housed in an AAALAC accredited 
University Animal Care Facility. 
Antibodies and Reagents. The anti-rabbit FAK antibody, the anti-mouse ERK2 
antibody (1B3B9), the anti-mouse Bcl-2 antibody, and the anti-rabbit Bax antibody 
were purchased from Upstate Biotechnology, Inc. The phosphospecific ERK1/2 
(p42/p44) antibody was purchased from Cell Signaling. The poly ADP-ribose 
polymerase-1 (PARP) antibody was purchased from Roche.  The cardiac troponin T 
monoclonal antibody (13-11) was a gift from Nadia Malouf (UNC, Chapel Hill).   
Unless specified, antibodies were used at 1/1000 dilution.  
Biomechanical stress. Mechanical stress was imposed on the left ventricle using 
the minimally invasive aortic banding as previously described [29].  Briefly, 20-30 g 
mice were anesthetized (sodium pentobarbital 0.06mg/gr IP), a small incision was 
made at the suprasternal notch and through the proximal portion of the sternum.  
Once the aortic arch was visualized, a 6.0 silk suture was placed under the aorta 
and tied tightly around the vessel using a blunt 27-gauge needle to establish the 
diameter of the ligature.  Sham-operated animals underwent an identical procedure 
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except for lack of ligature placement.   The skin was closed and the anesthetized 
animals were monitored on a heating pad until they recovered. The entire banding 
procedure lasted approximately 20 min per mouse.  Effectiveness of the procedure 
was monitored by measuring the pulsatility indices before and after banding by 
Doppler imaging.   An average 30-40 cm/sec rise in peak velocity (from a 65-75 
cm/sec baseline) in the right carotid with a concomitant decrease in the peak velocity 
of the left carotid was observed with no significant difference in the gradient between 
MFKO mice and genetic controls.  At end stage, the mice were euthanized by CO2 
inhalation and body weight was measured.  Following perfusion of the heart with 
phosphate buffered saline, the hearts and lungs were excised, weighed, and tissues 
were processed for RNA, protein, or histological analysis as described in detail 
below.  Although it has been reported that β-estrogen receptor signaling can lead to 
a depressed response to pressure overload induced-hypertrophy[152], we included 
both male and female mice in this study and found no gender difference in the 
propensity or extent of control or MFKO mice to undergo cardiac remodeling after 
TAC (data not shown).  All animal use procedures have been reviewed and 
approved by the University of North Carolina’s Animal Use and Care Committee. 
Transthoracic echocardiography.  Echocardiograph measurements were taken 
pre-operatively as well as the indicated time points after surgery using previously 
described methods [153].  Briefly, following light sedation with isoflurane, hair was 
removed from the chest and abdomen, and the mice are placed on a water-jacketed, 
warmed table in the left lateral decubitus position for imaging.  A Visualsonic 
Ultrasound System (Vevo 660) ultrasound machine containing a 30 Mhz variable 
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frequency pediatric probe with a 1 cm offset was used to capture the 
echocardiogram.  Standard long axis and short axis M-mode views were recorded 
when the mouse possessed a target heart rate between 450 and 650 beats per 
minute. End-diastolic and end-systolic interventricular septum (IVSd, IVSs), posterior 
wall thickness (PWTd, PWTs) and left ventricular internal diameters (LVEDD, 
LVESD) were calculated and averaged from three consecutive contractions using 
Visual Sonics software. Percent fractional shortening was calculated using: 
%FS={(LVEDD-LVESD)/LVEDD} x 100.  Relative wall thickness was calculated 
using: RWT={(IVSd + PWd)/2}/(LVEDD/2). An additional group of mice represented 
in supplemental data underwent echocardiograph measurements under heavier 
sedation with isoflurane to decrease the stress imposed in the animal and to aid in 
acquiring more accurate measurements. Although similar structural measurements 
were found, a dampened fractional shortening measurement was calculated likely 
due to decreased heart rates. 
Histological Analysis and Immunohistochemistry.  Paraffin-embedded hearts 
were sectioned into 8 μm slices and stained with Masson’s Trichrome stain (Sigma-
Aldrich) to assess overall morphology and presence of fibrosis.  Following the block 
of endogenous peroxidases with 0.3% H2O2 in methanol, sections were 
permeabilized with phosphate buffered saline containing 3% BSA w/ 0.2% Trition-X 
and then incubated with cardiac troponin T antibody in 1%BSA/PBS overnight at 4 
degrees C.  The sections were then washed with TBST (TBS plus 0.05% Triton-X), 
incubated with FITC- or Texas Red- conjugated donkey anti-mouse antibody for 90 
min. at RT, rinsed, and mounted with Vectamount (Vector Labs). Cell area 
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measurements were conducted on TRITC-Lectin (Sigma-Aldrich) stained cross 
sections of the compact zone of the heart muscle using Image J software (NIH).  
Electron Microscopy.  LVPW sections 1-2 mm3 in size were placed in a fixative 
overnight containing 2% paraformaldehyde and 2.5% glutaraldehyde in 0.15 M 
sodium phosphate buffer, pH 7.4 and postfixed for in 1% osmium tetroxide/1.25% 
potassium ferrocyanide in sodium phosphate buffer.  The tissues were rinsed in 
deionized water, dehydrated, and put through two changes of propylene oxide 
before embedding in epoxy resin. Representative longitudinal cells from the central 
LVPW were selected by light microscopy and 70 nm ultra thin sections were cut and 
collected on 200 mesh copper grids and stained with 4% aqueous uranyl acetate, 
followed by Reynolds’ lead citrate. Random fields from the left ventricular mid wall 
were scanned and 10-20 separate myocytes/condition were observed using a LEO 
EM910 transmission electron microscope at 80kV (LEO Electron Microscopy, 
Thornwood, NY) and photographed using a Gatan Bioscan Digital Camera (Gatan, 
Inc., Pleasanton, CA) [154].  
Quantitative RT-PCR. Ventricles were harvested from end stage banded or sham-
treated mice and placed in RNA later (Ambion). Samples were homogenized and 
RNA was extracted using Trizol reagent (Invitrogen) and quantified using Ribogreen 
spectrometry (Molecular Probes) according to the manufacturer’s protocol. Each 
sample of RNA was diluted to 50 ng/μl in DEPC treated H20. Each 30 μl RNA 
reaction mixture contained 0.5 μl of 0.1 μg/μl of primer, 1 μl of 20 μmol of probe 15μl 
of AB Gene one step master mix, and 0.1μl of RT enzyme.  The primers and probes 
used were as follows: ANF forward GAGAAGATGCCGGTAGAAGA, ANF reverse 
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AAGCACTGCCGTCTCTCAGA, ANF probe FAM-ATGCCCCCGCAGGCCCTG-
TAMARA, βMHC forward AGCTCAGCCATGCCAACCGT, βMHC reverse 
TGAGTGTCCTTCAGCAGACT, βMHC probe FAM-
AGGCTCTTCACTTGTTTCTGGGCCTCA-TAMARA, αMHC forward 
AGCTCAGCCAGGCCAATAGA, αMHC reverse TGGGTGTCCTTCAAGTGAGC, 
αMHC probe FAM-AGAATTCTTCAGGTGTTTCTGTGCCTCAG-TAMARA, skeletal 
α-actin forward TCCTCACTGAGCGTGGCTAT, skeletal α-actin reverse 
AGCTTCTCTTTGATGTCGCG, skeletal α-actin probe FAM-
CTTCGTGACCACAGCTGAACGTGAG-TAMARA, βactin forward 
CTGCCTGACGGCCAAGTC, βactin reverse CAAGAAGGAAGGCTGGAAAAGA, 
βactin probe FAM-CACTATTGGCAACGAGCGGTTCCG-TAMARA. c-Fos forward 
CAGTCAGAGAAGGCAAGGCA, c-fos reverse TCCTCTCTGTAATGCACCAG, c-
Fos probe FAM-CATCCAGACGTGCCACTGCCCGA-TAMARA.  
The real time-RT-PCR was performed using the ABI prism 7500 Sequence 
Detection System (PE Applied Biosystems) in 96-well plates under the following 
conditions:  30 minutes at 48 ˚C, 10 minutes at 95 ˚C, 40 cycles of 95 ˚C for 15 
seconds, then 60 ˚C for one min. For semi-quantitative RT-PCR analysis, each 20l 
reaction contained 250ng of ventricular RNA from end stage banded or sham-
treated mice, 4μl  reaction mix and 1μl reverse transcriptase using the iScript cDNA 
synthesis kit (BioRad). Each reaction was performed under the following conditions: 
5 minutes at 25 ºC, 30 minutes at 42 ºC, then 5 minutes at 85 ºC.  Each 50 μl PCR 
reaction mixture contained 2.5 μl of 10μM of primer, 4μl of dNTP mixture, 5μl of 
reaction buffer and 0.5 μl of TaKaRa Ex Taq enzyme. The reaction was performed 
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under the following conditions: 5 minutes at 94 ºC, 29 cycles of one minute at 94 ºC, 
one minute at 61 ºC, 2 minutes at 72 ºC, and then 10 minutes at 72 ºC. The primers 
used were as follows:  Bax forward GCGTCCACCAAGAAGCTGAG, Bax reverse 
ACCACC CTGGTCTTGGATCC, Bcl-2 forward TGTGGCCTTCTTTGAGTTCG, Bcl-2 
reverse TCACTTGTGGCCCAGGTATG. 
Western Blotting. Tissues were lysed in modified radioimmune precipitation assay 
buffer (50 mM Hepes, 0.15 M NaCl, 2 mM EDTA, 0.1% Nonidet -40, 0.05% sodium 
deoxycholate, pH7.2) containing 1 mM 4-(2-amnionethyl)benzenesulfonyl fluoride 
hydroxychloride, 0.02 mg/ml aprotonin containing 5% Triton-X. Proteins were boiled 
in a sample buffer and resolved using SDS-PAGE and transferred to nitrocellulose. 
Western blots were preformed using a 1/1000 dilution of the appropriate primary 
antibody.  Blots were washed in Tris-buffered saline, pH 7.4 plus 0.05% Triton-X, 
followed by incubation with either horseradish peroxide-conjugated protein A-
Sepharose (Amersham Bioscience) or horseradish peroxide-conjugated rabbit anti-
mouse antibody (Amersham Biosciences) at a 1/2000 dilution. Blots were visualized 
after incubation with chemiluminesence reagents (ECL, Amersham Biosciences). 
[155].  For quantitative measurements, blots were scanned and density was 
normalized to the density of a control protein for each sample.  
Cardiac Catheterization.  Mice were placed in a supine position, secured on the 
operating table, and anesthetized with inhaled isoflurane (3% for induction and 1-2% 
for maintenance). An approximately 1 cm midline incision from the lower mandible to 
the sternum was made, and the right common carotid artery was exposed and 
isolated by blunt dissection of the thin muscle layer around the trachea. A secure 
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suture was placed around the distal end of the artery and a loose suture was placed 
around the proximal end of the artery.  A small vascular clip was then placed on the 
proximal end of the artery to minimize bleeding during catheter insertion. A 1 - 2 mm 
incision was cut near the distal end of the artery and the tip of a 1.4 French catheter 
(Millar Instruments) was inserted in to the artery. Following removal of the vascular 
clip from the proximal end of the artery, the catheter was advanced beyond the 
proximal suture and the suture was tightened around the catheter shaft. The 
catheter was then advanced retrograde down the ascending aorta through the aortic 
valve in to the left ventricle. The catheter shaft was gently rotated to achieve optimal 
placement of the tips along the axis of the left ventricle. Measurements of steady 
state pressure volume loops were taken ten minutes following catheter placement. 
 Statistics.  Data are presented as mean ± SEM. Means were compared by 2-tailed 
Student’s t test. p<0.05 was considered statistically significant.  
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C. Results 
Myocyte-Restricted Deletion of FAK in Adult Mice  
 We used Cre/loxP technology to test the possibility that FAK inactivation could 
prevent cardiac hypertrophy in the intact myocardium.  To inactivate the fak gene in 
a myocyte-restricted fashion in mice, we bred fakflox mice to those that express Cre 
recombinase under the control of the ventricle specific mlc2v promoter (mlc2vCre/wt) 
[151] to obtain fakflox/floxmlc2vCre/wt mice; hereafter referred to as myocyte specific fak 
knockout mice (MFKO) (Figure 2.1a).   
 MFKO mice were born with the expected Mendelian frequency (Figure 2.1a), 
and we observed the selective appearance of the excised, recombined fak gene in 
the MFKO ventricles at 4-weeks postnatal (not shown), while maximal recombination 
occurred by 3-months (Figure 2.1b).  Western analysis confirmed that FAK protein 
was dramatically reduced in MFKO ventricular lysate by 3-months postnatal, 
whereas FAK protein levels remained constant in other tissues including skeletal 
muscle, stomach and brain (Figure 2.1c,d).  The low level of FAK protein remaining 
in the ventricular lysates from 3-months onward was likely due to its continuing 
expression in resident non-myocyte cells (i.e. cardiac fibroblasts, smooth muscle, 
and endothelial cells) that do not express Mlc2v.  
FAK is Not Required for Basal Cardiac Function 
  Disruption of FAK expression in the adult heart did not lead to any overt 
abnormalities.  Both sexes of MFKO mice lived a normal lifespan, were fertile, and 
females did not exhibit any complications during pregnancy, indicating that FAK is 
not required for the maintenance of normal heart function.  In confirmation of this, we 
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found no evidence of left ventricular dysfunction as assessed by fractional 
shortening (FS) and ejection fraction (EF) derived from M-mode echocardiographs of 
the left ventricle (LV) of young (4-months) or old (14-months) hearts from MFKO 
mice in comparison to aged matched genetic controls (Figure 2.2, Table 2.1).  At 14-
months of age both lines of mice had a significant reduction in FS and MFKO mice 
had a significant reduction in EF when compared to the 4-month-old controls, but no 
significant differences in these parameters were observed between age matched 
controls (Figure 2.2, Table 2.1). Importantly, no significant difference was observed 
in posterior or interventricular septal wall thickness (PW, IVS) or LV chamber size, 
between the 4-month-old MFKO and genetic controls {fakflox/floxmlc2vwt (Table 2.1) or 
fakwt/wtmlc2vCre (data not shown)}.  Hemodynamic analysis by cardiac catheterization 
also revealed no significant differences in intrinsic contractility, diastolic function, and 
cardiac output between control and MFKO mice at 4-months of age, consistent with 
a previous report (Table 2.2; [150]).   In addition 4-5-month-old MFKO mice had 
similar LVW:BW ratios (Figure 2.6a), cardiomyocyte cross-sectional area, 
myofibrillar organization, and levels of fibrosis compared to littermate controls 
(Figure 2.6b, 2.3a,b), indicating that the young MFKO mice are phenotypically 
indistinguishable from genetic controls.   
 Myocyte-restricted FAK deletion did have a slight but significant effect on heart 
growth during aging.  Left ventricular weight versus body weight was significantly 
decreased in 14-month MFKO mice relative to aged matched controls (Figure 2.2a). 
Additionally, myocyte cross-sectional area was reduced slightly (by 5%; p=0.04 Fig 
2b).  Consistent with these findings, serial echocardiograph measurements revealed 
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a significant increase in thickness of LV posterior wall from 4 to 14-months in control 
mice but not in MFKO mice (Table 2.1, Figure 2.2d).  Histological analysis of hearts 
from aged MFKO mice (14-months) revealed an increase in interstitial fibrosis in 
comparison to age matched controls (Figure 2.3a, Table 2.3), but no noticeable 
differences were found in sarcomeric integrity or myocyte alignment in comparison 
to hearts from age-matched control mice (Figure 2.3a, b).  Thus, the absence of FAK 
in cardiac muscle is functionally tolerated, but FAK may regulate anabolic myocyte 
growth as the heart ages.    
We next asked whether the depletion of FAK from myocytes was tolerated 
because of a compensatory increase in the FAK-related protein PYK2/CADTK which 
is known to have increased expression in fak-/- embryos and cells [156, 157].  
However, we found comparable PYK2 protein levels (and activity) in control and 
MFKO hearts (Figure 2.3c, data not shown), indicating that PYK2 does not 
compensate for loss of FAK in this model.    
Pressure-Overload-Induced Structural Remodeling and Hypertrophic Gene 
Expression is Attenuated in MFKO Mice 
 The absence of underlying developmental defects in the conditional MFKO 
mice at 4-5-months of age renders this model advantageous for determining whether 
FAK is important for the progression of pathological cardiac hypertrophy.  4-month-
old control and MFKO mice were therefore subjected to a minimally invasive aortic 
banding procedure that provided an approximate 50% reduction in the lumen of the 
ascending aorta.  Blinded echocardiograph measurements revealed several striking 
differences between the aged matched genetic controls and MFKO hearts following 
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4-weeks of transverse aortic constriction (TAC; Figure 2.4a,b, Table 2.I).  Notably, 
the control TAC mice developed significant thickening of LVPW and IVS 
(approximately 50% and 30% increases in systole respectively), a significant 
reduction in LVED (approximate 40% decrease in end diastolic chamber dimension), 
and a 40% increase in FS compared to non-banded control mice.  In contrast, the 
MFKO mice did not exhibit significant increases in LVPWT or FS comparison to the 
pre-banded MFKO mice (Table 2.1).  Indeed, the percent change of each parameter 
from pre to post TAC was significantly decreased in MFKO hearts in comparison to 
control hearts (Figure 2.4a).  Measurements from serial cross sections though 
banded control and MFKO hearts confirmed a significant reduction in relative 
LVPWT in 15/19 of the 4-week post TAC MFKO hearts in comparison to the control 
hearts (Figure 2.4b, Figure 2.5).  Importantly, morphometric analysis revealed a 
significant decrease in myocyte cross-sectional area in the post-TAC MFKO hearts 
compared to post-TAC controls (Figure 2.6b).  Although a significant increase in 
LVW/BW was observed following 4-weeks of TAC in MFKO hearts (possibly due to 
increased fibrosis, see below) the increase in MFKO hearts was reduced relative to 
control hearts (Figure 2.6a).  Notably, no significant difference in the surgically-
induced intensity of pressure-overload was observed between MFKO and the 
genetic controls as assessed by Doppler imaging (Figure 2.7a).  A comparable 
concentric hypertrophic response was observed in our two groups of control mice 
{fakflox/floxmlc2vwt (shown) and fakwt/wtmlc2vCre (data not shown)}, indicating that the 
lack of concentric hypertrophy observed in the MFKO mice was not due to adverse 
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effects of either the LoxP-targeted fak allele, expression of Cre, or haplo-
insufficiency of Mlc2v.   
 Recently, a separate report was published in which the authors suggested that 
cardiac-restricted inactivation of FAK leads to cardiac dilation due to an eccentric 
hypertrophic response [150].  Therein, Peng et. al. examined mice at only one time 
point following TAC (10 days) which was not sufficient to induce concentric 
hypertrophy in their control animals, but they observed a significant increase LV 
chamber dimension in their CFKO mice when compared to banded controls [150].  
To determine whether the change in chamber size was a primary or secondary 
response in our model, we banded a second group of mice (n=7 Control and MFKO) 
and examined their hypertrophic response by blinded echocardiography at 10-days 
and 4-weeks following TAC.  As shown in Figure 2.7b, no significant differences 
were observed between either LVPW or LVED between MFKO and control hearts at 
10-days following banding.  However, similar to our previous large study of mice 
(Table 2.I), this separate study revealed a significant decrease in LVPW in 4-week 
banded MFKO hearts in comparison to 4-week banded control hearts.  This change 
in LVPWT was accompanied by an increase in LVED in MFKO hearts relative to 
banded genetic controls, but like in our previous study MFKO LVED was not 
significantly increased from baseline MFKO hearts.  Since the echocardiograph 
measurements for this new data set were taken while mice were under heavier 
sedation the data were analyzed separately and are presented in full in Table 2.4.  
These studies confirm our contention that FAK inactivation inhibits the compensatory 
concentric hypertrophic response following TAC.    
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 Enhanced peri-vascular fibrosis as assessed by Masson’s Trichrome staining 
was observed following TAC in both control and MFKO TAC hearts with more 
interstitial fibrosis found in MFKO TAC hearts (blue staining, Figure 2.8a top, Table 
2.3). However, there was no significant difference in sarcomeric structure or integrity 
between control and MFKO hearts following TAC as visualized by troponin T 
staining (Figure 2.8a, 2.9).   
 There is some evidence indicating that the switch from hypertrophy to cardiac 
failure may involve activation of apoptotic pathways.  For instance, aortic banding of 
mice with heart-restricted deletion of the Gαq, MEKK1 and gp130 genes result in 
dilated cardiomyopathy accompanied by cellular apoptosis, an event presumably 
due to lack of activation of a critical survival signaling pathway during the 
hypertrophic process [109, 158, 159].  In some, but not all cell types, activation of 
FAK has been shown to be important for cell survival, and attenuating FAK signaling 
can lead to apoptosis [29, 31, 160, 161].  Although we did observe a greater extent 
of interstitial fibrosis in banded and aged MFKO hearts (likely due to increased 
myocyte drop-out), we did not observe an increase in apoptosis or apoptotic markers 
in control or MFKO hearts at baseline or following banding (Figure 2.9, 2.10). In 
addition, we found little if any evidence of apoptosis following TAC in either group as 
assessed by detection of DNA strand breaks by TUNEL (less than 0.03% TUNEL 
positive cells/condition, data not shown), PARP cleavage, or Bax/Bcl-2 expression 
levels (Figure 2.10b).  Accordingly, ultra-structural analysis by transmission EM 
showed no evidence of apoptosis or necrosis following 4 weeks of TAC (Figure 2.9).  
Both control and MFKO myocytes within the central posterior wall (most affected by 
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pressure overload) revealed intact myofibrils, well-organized sarcomeres and 
intercalated disks and no evidence of mitochondrial blebbing.  Thus, deletion of FAK 
does not appear to induce programmed cell death in mature cardiomyocytes. 
 Although PYK2 expression did increase following TAC, we found no significant 
difference in PYK2 levels (or activity) in MFKO TAC hearts relative to control TAC 
hearts (Figure 2.8, data not shown). Collectively, these data indicate that FAK is not 
required for the maintenance of proper myocyte architecture but is required for the 
promotion of biomechanical stress-induced myocyte hypertrophy.    
 Hearts from control and MFKO non-banded and 4-week TAC-induced mice 
were also analyzed for hypertrophic marker gene expression by quantitative RT-
PCR.  We examined the expression of atrial naturetic factor (ANF) because 
increased levels of this gene correlate highly with the degree of hypertrophy 
observed in several animal models [162].  As shown in Figure 2.11, ANF expression 
was, as expected, dramatically increased in the control mice after TAC. This 
increase was virtually abolished in the MFKO hearts (Figure 2.11a).  Interestingly, 
banded MFKO hearts displayed a significant increase in α-MHC compared to 
banded controls whereas no significant difference in βMHC or skeletal α−actin was 
observed between the two groups post-banding (Figure 2.11b, data not shown).  
Collectively our data indicate that loss of FAK alters the structural and a subset of 
the molecular changes induced by pressure-overload. 
Persistent Pressure-Overload in MFKO Mice Leads to Cardiac Dysfunction  
 Since the MFKO TAC hearts exhibited a reduced compensatory response 
following 4-weeks of pressure-overload, we asked whether the MFKO mice would 
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progress to heart failure after a more persistent challenge.  Although greater than 
90% survival was observed in control and MFKO mice banded for 8-12 weeks, the 
wet lung weights from the MFKO 8-week TAC group were significantly higher than 
non-banded mice, indicating substantial congestion, and the likelihood that the 
MFKO hearts were failing (Figure 12a).  Accordingly, significant depression of 
cardiac output, a measure of contractile performance, was apparent in MFKO mice 
12-weeks after TAC (Figure 2.12b).  The decreased contractility in the MFKO mice 
was associated with an increase in interstitial fibrosis relative to control-banded 
hearts at 8 and 12-weeks (Table 2.3).  However, sarcomeric integrity was 
maintained in these hearts as assessed by Troponin T staining (data not shown).  
These data indicate that the MFKO mice develop heart failure in response to chronic 
pressure-overload, and suggest the possibility that the blunted compensatory 
hypertrophic response in these mice was not sufficient to meet the increased 
hemodynamic demand.   
Absence of FAK Impairs MapKinase Activation Following Hypertrophic Stimuli 
 
 It is possible that the requirement for functional signaling through FAK in 
pressure-overload-induced hypertrophy may be due to the ability of FAK to co-
activate an essential growth pathway. Since ERK activation by hypertrophic stimuli 
precedes the characteristic changes in gene expression and inhibition of this 
signaling pathway can lessen maladaptive hypertrophic growth [163, 164], we 
evaluated ERK activity in control and MFKO hearts subjected to aortic banding for 1 
and 4 days.  Immunoblot analysis revealed reduced levels of ERK phosphorylation 
in MFKO hearts in comparison to control hearts after acute aortic constriction 
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although no change was observed at baseline (Figure 2.13a).  Since cardiac 
hypertrophy induced by pressure-overload and neuro-humoral signals share some 
common mechanisms, we also examined ERK activation induced by adrenergic 
agonists in control and MFKO hearts.  We injected an adrenergic cocktail previously 
shown to induce a strong hypertrophic response in mice [165].  As shown in Figure 
2.13b, ERK was strongly activated in control hearts following acute adrenergic 
agonist injection, but was significantly lower in the MFKO hearts.  We also examined 
activation of the immediate early gene cFos following acute banding.  We found that 
cFos expression was significantly up-regulated in control hearts 4 days after TAC, 
but returned to baseline by the 7 day time point (Figure 2.13c).   However, no 
significant increase in cFos expression was observed in MFKO hearts following 
banding, in accordance with data indicating that activation of cFos is dependent on 
ERK signaling (Figure 2.13c).  These data indicate that ERK activation is uncoupled 
in the absence of FAK, and highlight the possibility that FAK activity is required for 
the initial wave of signaling induced by both pressure-overload and adrenergic 
stress.  
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D. Discussion 
Previous work by our group and others indicate that FAK is important in the 
hypertrophic response.  Herein, we have used a mouse model in which myocyte-
restricted FAK deletion in early adulthood results in mice whose hearts are 
functionally and morphologically similar to those of control mice, confirming recent 
work from Peng et. al. [150]. However, we found that myocyte-restricted deletion of 
FAK depressed heart growth during aging and markedly reduced the hypertrophic 
response to transverse aortic constriction as assessed by examination of several 
conserved features of pathological hypertrophy.  Our data indicate that inhibition of 
FAK signaling alone is sufficient to suppress the diverse signaling inputs within the 
complex myocyte microenvironment in vivo that can modulate cardiac growth 
induced by stress and aging.   
Our findings that FAK inactivation attenuates concentric hypertrophic 
remodeling differ with the conclusions drawn in the aforementioned manuscript by 
Peng et. al. who observed chamber dilation (or eccentric growth) in FAK null hearts 
following 10 days of TAC [150].  This discrepancy could be due to differences in the 
timing of FAK deletion, the extent of aortic constriction imposed in the two models 
and/or the genetic background of the mice used in these studies. Our findings that 
FAK inactivation attenuates concentric hypertrophic remodeling differ with the 
conclusions drawn in the aforementioned manuscript by Peng et. al. who observed 
chamber dilation (or eccentric growth) in FAK null hearts following 10 days of TAC 
[150].  As mentioned above, this discrepancy could be due to differences in the 
timing of FAK deletion, the extent of aortic constriction imposed in the two models 
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and/or the genetic background of the mice used in these studies.  Notably, 
phenotypic diversity in cardiac morphology and response to cardiac pressure 
overload have been found between the most commonly used inbred mouse strains 
C57BL/6J (B6) and 129S1/SvImJ (129) [166, 167].  Although original engineering of 
our mice occurred on a 129 background, all mice used for our studies were 
backcrossed against B6 at least 8 generations.  Thus, if the mice used in the Peng 
et. al. study were on a 129 or mixed background, this could explain our disparate 
findings.  In addition, different Lox P-targeted fak mice were used for these studies, 
and temporal differences in FAK depletion were observed.  Notably, the Peng et. al. 
study observed significant FAK protein depletion by 2 weeks postnatal, while in our 
study FAK protein levels were not significantly altered until 12 weeks postnatal.  
Thus, it is possible that the earlier onset of FAK inactivation in their study could have 
led to an underlying cardiac defect prior to banding that was exacerbated upon 
pressure-overload.  In support of this contention, the FAK null hearts from the Peng 
et. al. study were reportedly failing by 9 months of age, while systolic function is 
maintained in our mice for at least 14 months of age and we have not observed any 
spontaneous or pregnancy-related mortality.   
 The late onset of recombination in our model system (3 months post-natal) 
was somewhat surprising since the mlc2v-promoter has been reported to drive Cre 
expression as early as embryonic day 8.5, however our results are consistent with 
several studies showing that maximal recombination of targeted genes is not 
observed until at least 6 weeks after birth (and some even later) using the same line 
[134, 168].   A distinct advantage of using our MFKO line is that it enables 
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examination of a direct role for FAK in the progression of adult onset cardiac 
diseases in mice that do not have any underlying developmental defects. 
It is interesting that FAK is dispensable for basal myocyte function, while 
depletion of integrin receptors or various cytoskeletal components including vinculin, 
muscle LIM protein, desmin, plakoglobin, or N-cadherin all lead to rapid defects in 
sarcomeric integrity accompanied by considerable interstitial fibrosis [132]. These 
data indicate that although FAK co-resides with these cytoskeletal proteins in Z-
disks, it is not an integral component of the contractile apparatus in myocytes.  
However, we did find that following persistent challenge MFKO hearts exhibited 
systolic dysfunction relative to control-banded hearts.  This was likely a secondary 
effect due to insufficient compensation in response to TAC, since this model induces 
a rapid and severe remodeling response in control animals.  There is some evidence 
indicating that the switch from hypertrophy to cardiac failure may involve activation of 
apoptotic pathways.  Although we did observe a greater extent of interstitial fibrosis 
in banded and aged MFKO hearts (likely due to increased myocyte drop-out), we did 
not observe an increase in apoptosis or apoptotic markers at the time points 
examined.  These data corroborate our previous studies showing that FAK inhibition 
in cultured cardiomyocytes did not induce programmed cell death and studies from 
others indicating that targeted deletion of FAK in keratinocytes or neurons did not 
induce apoptosis [29, 141, 161].  Taken together, these data indicate that the 
ensuing dysfunction in MFKO hearts is likely due to a passive necrotic process. 
   As a multi-functional adapter protein that associates with the integrin 
cytoplasmic tail, with actin, and with several adapter proteins that regulate various 
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catalytic signaling molecules, FAK is an ideal candidate to sense and respond to 
hormonal imbalances and/or alterations in the force-generating actin cytoskeleton by 
inducing coordinate activation of downstream hypertrophic growth signaling 
pathways. Our study revealed that myocyte-specific depletion of FAK dramatically 
reduces biomechanical stress or hypertrophic agonist–stimulated ERK activation.  
Given that activation of the MEK1-ERK1/2 signaling pathway in vivo precedes the 
induction of hypertrophic gene expression and that inhibition of these signaling 
pathways can lessen hypertrophic growth, it is reasonable to assume that reduced 
ERK activation may be the primary mechanism responsible for the blunted 
hypertrophic response in MFKO hearts [131, 163, 164].   
In conclusion, our analysis of MFKO mice reveals that FAK is essential for the 
heart to sense and transduce a biomechanical insult into a compensatory 
hypertrophic response.  This effect is likely due to the ability of FAK to modify the 
initial wave of ERK-dependent signaling induced by hypertrophic stimuli.  Since 
cardiac hypertrophy induced by pressure-overload and neuro-humoral signals share 
common mechanisms, and since signaling from adrenergic receptors is depressed 
in MFKO hearts, it is possible that activation of FAK may be a common requirement 
for the initiation of the pathological hypertrophic response.  Interestingly, recent 
studies have shown that while disruption of MEKK1 (like FAK) eventually leads to 
cardiac de-compensation following pressure-overload, inactivation of MEKK1 
actually prevents systolic dysfunction induced by Gαq [169, 170].  Thus, further 
studies coupling various hypertrophic model systems with cardiac-targeted FAK 
disruption should lead to important new information with regard to the transition from 
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compensatory to de-compensated stages of cardiac hypertrophy and aid in 
determining under which circumstances FAK-dependent signaling pathways may be 
protective or detrimental.  Whether targeted inhibition of FAK would be beneficial for 
the treatment of heart disease will likely depend on the contributing factors for 
disease.   
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Figure 2.1. Targeted Myocyte Specific Disruption of Mouse Focal Adhesion 
Kinase.  a, Diagrammatic representation of the fakflox/flox and mlc2vCre/wt breeding 
strategy (n=725).  b, PCR analyses of heart DNA from wild type mice (wt, 1.4 kb 
band), Flox (1.6kb band), and MFKO mice (recombined allele generates 327 bp 
band). c, Protein extracts from 3-month-old control (C) and MFKO ventricles were 
processed by SDS-PAGE and probed with anti-FAK or anti-ERK antibodies. 
Densitometry quantification of FAK expression compared to an ERK loading control 
(right, n=3). d, Protein extracts from skeletal muscle, stomach, and brain from 3-
month-old control (C) and MFKO mice processed as described above using an anti-
FAK antibody.  
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Figure 2.2. FAK is Required for Myocyte Growth. a, Baseline function of 4-month 
and 14-month-old control (C) and MFKO hearts as determined by M-mode 
echocardiography (*, p<0.05 when compared to baseline genetic control; see Table I 
for measured values and number of mice/condition). b, LV weight (LVW) to body 
weight (BW) ratio for 14-month-old control (n=10) and MFKO (n=6) mice. *, p<0.05. 
(bottom panel) c, Cross sectional myocyte area of control and MFKO myocytes from 
14 month old hearts, n=at least 285 per condition. *p, <0.05 compared to control. d, 
Left ventricular posterior wall thickness measured in control and MFKO 14 month old 
hearts. *p,<0.05 compared to control (bottom).  
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Figure 2.3. FAK is Not Required for Maintenance of Myocyte Cyto-Architecture. 
a, Left ventricles from indicated ages of control and MFKO mice were processed for 
histology as described in the Materials and Methods section and stained with 
Masson’s Trichrome to reveal myocyte organization and level of fibrosis (blue). b, 
Sections of left ventricle from control and MFKO mice were stained with an anti-
cardiac troponin T antibody to reveal myofibrillar organization. c, Immunoblot of 
protein extracts from 4-month control or MFKO ventricles were probed with  anti-
Pyk2 (top) or anti-ERK antibodies (bottom). Densitometry quantification of Pyk2 
expression compared to an ERK loading control (right, n=4).  
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Figure 2.4. FAK is Essential for Pressure-Overload-Induced Hypertrophy. a, M-
mode echocardiograph measurements of the left ventricles from baseline and 
banded control and MFKO mice during diastole (d) and systole (s) were analyzed for 
percent change from pre to post TAC. *, p<0.05 when compared to percent change 
in control mice. b, Ventricles from sham and 4-week banded control and MFKO 
hearts were stained with Trichrome to reveal gross changes in wall thickness and 
chamber dimensions following 4-weeks of TAC.  
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Figure 2.5. FAK is Required for Increased Posterior Wall Thickness. Relative 
wall thickness (RWT) measured in 15/19 MFKO hearts show a significant reduction 
compared to control. *p,<0.05. 
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Figure 2.6. MFKO Hearts Have Reduced Myocyte Area. a, Left ventricular weight 
(LVW) to body weight (BW) ratio. b. Cross-sectional myocyte area of sham and 4 
week banded control and MFKO myocytes (middle, n=at least 175 per condition).    
*, p<0.05 for indicated comparison. Representative LV sections stained with lectin 
reveals reduced cross-sectional area in MFKO myocytes compared to controls 
following 4-weeks of TAC (bottom). 
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Figure 2.7. Functional and morphological changes induced by TAC in control 
and MFKO mice.  a, Doppler measurements from the left and right carotid arteries 
prior to and immediately following aortic constriction were compared for changes in 
peak velocity. Similar changes were measured in both control (C) and MFKO mice. 
b,  Comparison of left ventricular posterior wall and chamber size in both control and 
MFKO mice. *, p=0.01 versus control 4-week banded control.  
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Figure 2.8.  Post TAC MFKO Hearts Have Increased Fibrosis but MFKO 
Myocytes Display Normal Cyto-Architecture.  a, 10X images of Trichrome-stained 
sections (top) or 40X images of sections stained with cardiac troponin T antibody 
(bottom) reveal increased fibrosis but normal cell-cell interactions and myofibrillar 
organization in control and MFKO hearts. b, Western blot analysis of Pyk2 protein 
levels following 4-week TAC of control (C) and MFKO mice. Densitometry 
quantification of Pyk2 expression compared to an ERK loading control (right, n=5).   
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Figure 2.9. MFKO Hearts Have Similar Ultra-Structure as Controls. 
Transmission electron micrographs from the mid-wall region of the left ventricle of 4-
week banded control and MFKO mice taken at 4000x, 10000x and 20000x 
magnification.   
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Figure 2.10. FAK Deletion Does Not Alter Expression of Apoptotic Markers.  a, 
Ventricular lysate from baseline and 4 week TAC control (C) and MFKO mice was 
processed for Western analysis using anti-PARP antibody.  Amount of cleaved 
PARP was quantified by densitometry. Data are presented in comparison to an ERK 
loading control (n=4).  b, Top panel shows RTPCR analysis of Bax and Bcl-2 mRNA 
from sham and 28d banded control (C) and MFKO (M) mice. Bottom panel shows 
Western blot analysis of Bax and Bcl-2 protein levels from control and MFKO mice 
following 4 weeks of TAC.  Right panel shows quantification of Bax to Bcl-2 protein 
levels (n=4). 
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Figure 2.11. FAK Modulates ANF Expression Following TAC.  Quantitative RT-
PCR analysis for ANF (a) and αMHC (b) RNA levels from sham and banded control 
and MFKO hearts. Data were normalized to β-actin levels and presented as fold 
over values from sham control mice. *, p = 0.03 versus banded control.   
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Figure 2.12. Chronic Banding Leads to Systolic Dysfunction in MFKO Mice. a,  
Wet lung and body weight measurements were taken from control and MFKO sham-
treated mice or mice banded for 4 or 8-weeks. *, p=0.03 versus experimental control 
n=4 (or more) for each group. b, Sham or 12-week banded control and MFKO mice 
were subjected to cardiac catheterization as described in the Materials and Methods 
section to examine contractile function. n=at least 4 for each group. *, p=0.03 versus 
12-week banded control. 
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Figure 2.13. FAK is Required for Maximal ERK Activation Induced by Banding 
and Adrenergic Stress.  a, Western blot analysis of phopspho-ERK1/2 following 
one or four days of aortic constriction in control and MFKO mice. Densitometry 
quantification of phospho-ERK1/2 compared to an ERK loading control (right, n=3).  
b, Control (C) and MFKO mice were injected with a adrenergic cocktail for 7 min 
containing PE and isoproterenol (30 mg/kg each) or PBS into the intraperitoneal 
cavity. Ventricular lysate was processed for Western blot analysis using anti-FAK, 
phospho-ERK1/2, and total ERK 1/2 (loading control) antibodies. Densitometry 
quantification of phospho-ERK1/2 compared to an ERK loading control (right, n=3). 
c, RNA was extracted from control and MFKO hearts at days 0, 4, and 7 following 
banding and processed for quantitative RT-PCR using the c-fos probe and primers 
detailed in the Materials and Methods section *, p = 0.03 versus 4-day banded 
control mice. 
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 Chapter  III 
FAK ACTIVITY IS NECESSARY AND SUFFICIENT TO INDUCE CARDIAC 
HYPERTROPHY 
A. Introduction 
 Hypertrophy, broadly described as an increase in growth, can manifest in 
distinct pathologies in the heart.  Chronic exercise training can induce a beneficial 
adaptive response on the cardiovascular system causing cardiac hypertrophy which 
is referred to as an athletic heart or physiological hypertrophy [171].  These 
adaptations help the heart meet the increased hemodynamic demands, enhancing 
normal cardiac function [172]. On the other hand, chronic pressure overload induced 
by neuroendocrine and autocrine factors leads to a distinct form of cardiac 
hypertrophy termed pathological hypertrophy. Initially, this response is 
compensatory as the increased heart size can help maintain function in response to 
the increased demand [173].  However, over time this leads to decreased left 
ventricular cardiac function and subsequent heart failure [173]. The latter is likely 
due to changes in gene expression that do not occur in physiological hypertrophy 
including alterations in a number of calcium handling proteins. The differential 
responses observed in physiological and pathological hypertrophy are likely due to  
differential signaling pathways at the cellular level [174]. Although many molecules 
have been defined to have a specific role in either pathological or physiological 
hypertrophy, the further delineation of the distinct signaling pathways is critical for 
the treatment of heart disease (Figure 1.4).  
 Normal cardiac growth and physiological hypertrophy are largely mediated 
through insulin growth factor-1 (IGF-1) and growth hormone (GH). IGF-1 activates 
the PI3K subunit a (p110a) which activates downstream effectors such as the 
serine/threonine kinase AKT and its activator 3-phosphoinositide-dependent protein 
kinase-1 (PDK-1) [81-83].  AKT is required for normal heart growth and regulates the 
hypertrophic response through signals to mTOR and GSK3β, which regulate the 
synthesis of proteins involved in hypertrophy [92, 93]. 
 A variety of cellular receptors are responsible for the initiation of pathological 
hypertrophy. Ligands such as phenylephrine (PE), angiotensin II (AngII), and 
endothelin-I activate GPCR’s, specifically Gq, and trigger the induction of cardiac 
hypertrophy in vitro [100-102]. In vivo studies have also implicated a role for  
GPCR’s in pressure overload ventricular hypertrophy[103]. Transgenic mice that 
over express either Gαq, α1-adrenergic receptors (ARs), or AngII receptors in 
myocytes all develop cardiac hypertrophy [104-106].  The specific downstream 
pathways initiated in the pathological hypertrophic response have been reviewed 
earlier in this thesis.  
Although precise characterization of the pathways that lead to detrimental 
versus compensatory responses and the plethora of gene expression changes are 
not clear at present, data from our lab and others indicate that Focal Adhesion 
Kinase (FAK), a ubiquitously expressed cytoplasmic tyrosine kinase, may play a key 
role in cardiomyocyte hypertrophy. As noted previously in this thesis, pathological 
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hypertrophy is characterized by an increased accumulation of extracellular matrix 
(ECM) proteins, such as fibronectin(FN) [107]. The deposition of ECM proteins is 
thought to contribute an additional layer of stiffness to the heart as well as to 
enhance signaling cascades.  FAK is strongly activated by integrins and 
neurohumoral factors, and a variety of in vitro and in vivo studies have implicated 
FAK in the progression of cardiac hypertrophy following mechanical and adrenergic 
stimuli.  
Past in vitro work from our laboratory demonstrated that cells expressing the 
dominant negative of FAK, FRNK, displayed an inhibition of PE induced 
cardiomyocyte hypertrophy as assessed by cell size, sarcomeric reorganization, and 
endogenous ANF staining [38].  Subsequent reports showed that over expression of 
FRNK also attenuated endothelin-I and stretch/AngII stimulation of hypertrophy [129, 
130]. Following pressure overload in the adult rat heart, FAK tyrosine 
phosphorylation is increased [145].  Further examination showed that in addition to 
activation of FAK, a variety of downstream effectors of FAK including p130Cas, 
Grb2, ERK1/2, AKT, and PI3K were activated [145, 175].  Work described in 
Chapter III of this thesis demonstrates that in vivo deletion of FAK is able to block 
the pressure-overload induced hypertrophic response.  
Although past work has established a role for FAK protein in the progression 
of hypertrophy, it is presently unclear whether FAK activity is necessary and 
sufficient for the initiation of pathological cardiac hypertrophy.  We recently 
generated a line of mice that enabled us to examine the effect of FAK deletion in the 
progression of pathological hypertrophy. This model utilized Cre/loxP technology to 
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specifically delete FAK protein from the myocardium and led to maximal protein 
deletion at 3-months postnatal [33]. The delay in recombination, due to (suboptimal) 
gene accessibility of the endogenous gene as well as a relatively long half life of 
FAK protein, made it impossible to study the role of FAK in anabolic growth and 
early stages of cardiac development. To circumvent these problems, we inhibited 
FAK activity in the adult myocardium using a transgenic mouse which expresses 
MycFRNK in the myocardium to determine if FAK activity is necessary for the 
progression of hypertrophy. This model will target FAK activity earlier than the FAK 
deletion model in Chapter II (MFKO) since Cre initiated gene recombination and 
expression of protein (in this case MycFRNK), will occur earlier than recombination 
of a floxed allele and deletion of the gene of interest. We reasoned that ectopic 
expression of this endogenous dominant negative would be a good model to study 
the effect of FAK activity on cardiac development and anabolic growth.  
Our studies reveal that inhibition of FAK in the postnatal heart does not alter 
anabolic growth, but attenuates pressure overload induced hypertrophy. To test the 
possibility that active FAK is sufficient to induce cardiac hypertrophy in vivo, we next 
generated a novel mouse model that produces cardiomyocyte-specific expression of 
a constitutively active form of FAK, termed SuperFAK.  We show that expression of 
this protein is sufficient to induce cardiac hypertrophy in the absence of surgical 
manipulation. Initial gene expression data from one of the SuperFAK transgenic 
lines reveals that the hypertrophy observed resembles a classic pathological 
hypertrophic response. However, further studies are required to distinguish between 
the pathological and physiological hypertrophic response in these mice.  
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B. Materials and Methods 
Generation of MycFRNK Mouse.  A 1.4kb fragment of MycFRNK was amplified out 
of the pRK5MycFRNK vector to incorporate 3’ and 5’ Not1 sites with an internal Kpn 
site [38].  This fragment was then ligated into a cassette in which a piece of the 
βactin promoter is fused to cDNA containing GFP flanked by loxP sites. Ultimately, 
the CX1-MycFRNK fragment was cut out using Kpn, linearized, and submitted for 
pronuclear microinjection into 0.5 day fertilized embryos which was performed within 
the UNC Animal Models Core Transgenic Facility at the University of North Carolina 
at Chapel Hill.  All mice were backcrossed to the C57black6 background at least 8 
generations prior to subsequent breeding.  DNA isolated from tail snips or tissues 
was subjected to PCR analysis using primers specific for the MycFRNK transgene 
(CGCGGTACCATCCAGACATGATAAGATACATTGATGAG and 
CGCCTCGAGGCTGCCACCATGGAGCAGAAGCTGATC). Dr. Kenneth Chien 
(Harvard) graciously provided the mlc2vCre knock-in mice. Mice were housed in an 
AAALAC accredited University Animal Care Facility. 
Generation of the SuperFAK Mouse. A 3.2 kb Not1 fragment comprising the 
modified βMHC promoter was amplified from a vector and ligated into a pBKS 
plasmid [32]. SuperFAK was amplified from a pBKS plasmid and cloned into a flag 
vector with BamHI and XhoI sites using standard procedure [176]. FlagSuperFAK 
was subsequently cut from the flag vector using NotI and SpeI to place it 
downstream of the βMHC promoter in the pBKS plasmid.  Pronuclear microinjection 
of the linearized βMHCflagSuperFAK plasmid into 0.5 day fertilized embryos was 
performed at the UNC Animal Models Core Transgenic Facility at the University of 
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North Carolina at Chapel Hill. Transgene expression in C57/Bl6 X C3H hybrid strain 
founders and F1 progeny mice were confirmed by PCR analysis using primers 
specific for the SuperFAK transgene (CCGGCATGGAGATGCTACTG, and 
GCGGCCGCAAGCTGCCACCATGGACTACAAGG).  Six founder mice tested 
positive for the βMHCflagSuperFAK transgene. However, of these six, two 
expressed the flag-SuperFAK protein in the heart.  These lines were breed with 
black6 mice and F1 progeny characterized. All transgenic mouse procedures were 
performed in accordance with guidelines set forth by the Institutional Animal Care 
and Use Committee (IACUC). 
Western Blotting. Tissues were lysed in modified radioimmune precipitation assay 
buffer (50 mM Hepes, 0.15 M NaCl, 2 mM EDTA, 0.1% Nonidet -40, 0.05% sodium 
deoxycholate, pH7.2) containing 1 mM 4-(2-amnionethyl)benzenesulfonyl fluoride 
hydroxychloride, 0.02 mg/ml aprotonin containing 5% Triton-X. Proteins were boiled 
in a sample buffer and resolved using SDS-PAGE and transferred to nitrocellulose. 
Western blots were preformed using a 1:1000 dilution of the appropriate primary 
antibody.  Blots were washed in Tris-buffered saline, pH 7.4 plus 0.05% Triton-X, 
followed by incubation with either horseradish peroxidase-conjugated protein A-
Sepharose (Amersham Bioscience) or horseradish peroxidase-conjugated rabbit 
anti-mouse antibody (Amersham Biosciences) at a 1:2000 dilution. Blots were 
visualized after incubation with chemiluminescence reagents (ECL, Amersham 
Biosciences)[155].  
Histological Analysis and Immunohistochemistry.  Paraffin-embedded hearts 
were sectioned into 8 μm slices and stained with Masson’s Trichrome stain (Sigma-
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Aldrich), to assess overall morphology and presence of fibrosis, and hematoxylin 
and eosin for overall morphology. Following the block of endogenous peroxidases 
with 0.3% H2O2 in methanol, sections were permeabilized with phosphate buffered 
saline containing 3% BSA w/ 0.2% Triton-X and then incubated with cardiac troponin 
T or GFP antibody in 1%BSA/PBS overnight at 4 degrees C.  The sections were 
then washed with TBST (TBS plus 0.05% Triton-X), incubated with Texas Red- 
conjugated donkey anti-mouse antibody or horseradish peroxidase conjugated anti-
mouse antibody for 90 min. at room temperature (RT), rinsed, and mounted with 
Vectamount (Vector Labs). Cell area measurements were conducted on TRITC-
Lectin (Sigma-Aldrich) stained cross sections of the compact zone of the heart 
muscle using Image J software (NIH).   
Antibodies and Reagents. The FAK, ERK2 (1B3B9), and cortactin (4F11) 
antibodies were purchased from Upstate Biotechnology, Inc. The phosphospecific 
ERK1/2 (p42/p44) antibody and monoclonal Myc antibody was purchased from Cell 
Signaling. The caspase-3 antibody was purchased from Cell Signaling. The GFP 
(AV polyclonal) antibody was purchased from ClonTech. The phosphospecific 
tyrosine-397 antibody was purchased from Biosource.  The monoclonal M2 flag 
antibody was purchased from Sigma-Aldrich. The cardiac troponin T monoclonal 
antibody (13-11) was a gift from Nadia Malouf (UNC, Chapel Hill).  Unless specified, 
antibodies were used at 1:1000 dilution.  
Transthoracic Echocardiography.  Echocardiograph measurements were taken at 
the indicated time points using previously described methods[177].  Briefly, following 
light sedation with isoflurane, hair was removed from the chest and abdomen, and 
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the mice were placed on a water-jacketed, warmed table in the left lateral decubitus 
position for imaging.  A Visualsonic Ultrasound System (Vevo 660) ultrasound 
machine containing a 30 MHz variable frequency pediatric probe with a 1 cm offset 
was used to capture the echocardiogram.  Standard long axis and short axis M-
mode views were recorded when the mouse possessed a target heart rate between 
450 and 650 beats per minute. End-diastolic and end-systolic interventricular septum 
(IVSd, IVSs), posterior wall thickness (PWTd, PWTs) and left ventricular internal 
diameters (LVEDD, LVESD) were calculated and averaged from three consecutive 
contractions using Visual Sonics software. Percent fractional shortening was 
calculated using: %FS=(LVEDD-LVESD)/LVEDD (x 100).   
Quantitative RT-PCR. Ventricles were harvested from end stage mice, 
homogenized, and RNA was extracted using Trizol reagent (Invitrogen). Each 
sample of RNA was diluted to 50 ng/μl in DEPC treated H20. Each 30 μl RNA 
reaction mixture contained 0.5 μl of 0.1 μg/μl of primer, 1 μl of 20 μmol of probe 15μl 
of AB Gene one step master mix, and 0.1μl of RT enzyme.  The primers and probes 
used were as follows: ANF forward GAGAAGATGCCGGTAGAAGA, ANF reverse 
AAGCACTGCCGTCTCTCAGA, ANF probe FAM-ATGCCCCCGCAGGCCCTG-
TAMARA, βMHC forward AGCTCAGCCATGCCAACCGT, βMHC reverse 
TGAGTGTCCTTCAGCAGACT, βMHC probe FAM-
AGGCTCTTCACTTGTTTCTGGGCCTCA-TAMARA, αMHC forward 
AGCTCAGCCAGGCCAATAGA, αMHC reverse TGGGTGTCCTTCAAGTGAGC, 
αMHC probe FAM-AGAATTCTTCAGGTGTTTCTGTGCCTCAG-TAMARA, 18s 
forward  AGAAACGGCTACCACATCCA, 18s reverse 
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CTCGAAAGAGTCCTGTATTGT, 18s probe TET-
AGGCAGCAGGCGCGCAAATTAC-TAMARA. The real time-RT-PCR was 
performed using the ABI prism 7500 Sequence Detection System (PE Applied 
Biosystems) in 96-well plates under the following conditions:  30 minutes at 48 ˚C, 
10 minutes at 95 ˚C, 40 cycles of 95 ˚C for 15 seconds, and then 60 ˚C for one min.  
Statistics.  Data are presented as mean ± SEM. Means were compared by 2-tailed 
Student’s t test. p<0.05 was considered statistically significant. 
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C. Results 
Generation of CX1frnk Mice. 
 Our success with using FRNK over-expression to inhibit FAK activity in the 
neonatal cell culture model prompted us to use the same approach to study the role 
of FAK signaling in the myocardium in vivo. To this end we have generated a Cre 
recombinase-based transgenic mouse model in which FRNK can be over-expressed 
in a time and tissue-restricted fashion under the indirect control of Cre expression. In 
this expression system the gene of interest (e.g. MycFRNK) is cloned downstream of 
a region of the β-actin promoter that drives high level expression in all tissues. 
However, a GFP reporter followed by a transcriptional ‘stop’ site has been inserted 
upstream of the transgene, preventing expression of MycFRNK.  Importantly, the 
GFP-‘stop’ codon region is flanked as a unit by loxP sites, which direct Cre-mediated 
excision (Figure 3.1a).  Thus the CX1-stop-transgenic mice can be crossed with a 
second line of mice that express the Cre recombinase under the control of a cell or 
tissue-specific promoter.   
To test the MycFRNK construct, cultured cells were transfected with the 
MycFRNK transgene and then infected using a Cre recombinase adenovirus. Cell 
lysates were acquired at various time points following infection and immunoblot 
analysis was performed on the lysate for both FRNK and GFP. As expected, in the 
presence of Cre, FRNK expression was induced and the expression of GFP 
decreased over time (Figure 3.1b).  
 Results shown in Figure 3.1c demonstrate that this approach enabled tight 
control of MycFRNK expression in vivo.  Western blot analysis revealed moderate 
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levels of GFP in all tissues examined including aorta, brain, heart, lung, esophagus, 
bladder, stomach, intestine, kidney, skeletal muscle, and uterus, while MycFRNK 
was undetectable in these lysates. Immuonhistochemistry for GFP expression 
revealed uniform expression throughout the heart, confirming that the transgene 
does not result in a variegated expression pattern (Figure 3.1d).   
Ventricle targeted expression of FRNK 
 To explore the role of FAK in cardiac development and anabolic growth of the 
heart, we generated an inducible transgenic line with myocyte restricted FAK 
expression (Figure 3.1a).  The MycFRNK transgenic mouse, herein termed CX1frnk   
was bred to the previously described MLC2vCre line to generate a line of myocyte-
restricted FRNK expressing mice (Figure 3.2a) [159, 178]. CX1frnkMLC2vCre mice are 
born with Mendelian frequency, have a normal life expectancy and do not have any 
overt abnormalities (Figure 3.2b). As shown in Figure 3.3d, comparable levels of 
FRNK are expressed in cardiac lysates from 1 day to 10 months postnatal.  
However, expression of FRNK in embryonic heart lysate was undetectable. 
Accordingly, histological analysis revealed that these hearts developed normally. 
Notably, in the presence of Cre, MycFRNK expression was restricted to heart and 
was not expressed in the skeletal muscle or stomach, indicating that unwanted 
“read-through” expression did not occur in vivo (Figure 3.2e).  Importantly, hearts 
from CX1frnkMLC2vCre mice exhibit decreased FAK activity relative to hearts from 
control mice (CX1frnkMLC2vwt/wt) as determined by Western blotting with an anti-
pFAK Y-397 antibody (Figure  3.2f).   
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Histological and Functional analysis of CX1frnkMLC2vCre hearts 
 Histological analysis revealed that hearts from MycFRNK mice had similar 
cardiomyocyte size, myofibrillar organization, and extent of collagen deposition as 
compared to hearts from littermate control mice from 2 to 8 months of age (Figure 
3.3a).  Sarcomeric organization was intact and comparable in both control and 
MycFRNK mice as demonstrated by cardiac troponin T staining. Cardiomyocyte 
area was not significantly different between 8 week old control and MycFRNK hearts 
(Figure 3.3b,c).  Additionally, heart weight versus body weight measurements taken 
from CX1frnkMlc2vcre and control mice at 2 months postnatal was similar between the 
two groups (Figure 3.4a). Physiological evaluation of CX1frnkMlc2vcre mice via 
echocardiography revealed that FRNK overexpression does not alter cardiac 
development or function (Table 3.1).  These data imply that the presence of FRNK in 
the cardiomyocytes does not affect anabolic growth of the heart.  
CX1frnkMLC2vCre Mice Exhibit a Delayed Hypertrophic Response 
We recently published a report showing that myocyte-restricted FAK deletion 
attenuates compensatory hypertrophic remodeling following pressure-overload [33]. 
This finding highlights the possibility that FAK activity is required for the initiation of 
this compensatory response. The utilization of FRNK as a dominant negative for 
FAK will enable us to dissect FAK’s role as a scaffold compared to its role as a 
signaling molecule to further explore the requirement for full FAK activity in the 
progression of cardiac hypertrophy in vivo. Thus, we next subjected CX1frnkMLC2vCre 
and wild type littermate control mice to a minimally invasive aortic banding 
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procedure that provides an approximate 50% reduction in the lumen of the 
ascending aorta [177]. 
  Following chronic aortic constriction, we inspected the mice for a variety of 
hypertrophic changes.  At 14 days post banding, there was a significant increase in 
heart weight versus body weight in both genetic control and CX1frnkMLC2vCre mice. 
However, the CX1frnkMLC2vcre mice had significantly lower heart weight versus body 
weight in comparison to genetic controls following banding (Figure 3.4a). In addition, 
the genetic control mice exhibited significant increases in the diameters of the left 
ventricular wall (LVPW) and interventricular septum (IVS) at the expense of the left 
ventricular chamber following 14d of aortic banding. By contrast, we saw no 
significant changes in these parameters in the CX1frnkMLC2vCre mice, as expected 
from our previously published account in MFKO mice (Figure 3.4b) [33].  The 
decreased wall thickness was likely due to decreased cardiomyocyte cell 
hypertrophy, since prolonged aortic constriction revealed a significant decrease in 
myocyte cross sectional area in CX1frnkMLC2vCre hearts compared to wild type 
(Figure 3.4c). In addition, the fold increase in ANF expression via quantitative 
RTPCR analysis in these hearts following banding was significantly decreased (66 
fold increase, control; 3.8 fold increase, FRNK; data not shown). Overall, these 
findings corroborate our previous studies in the MFKO mice (Chapter II) and 
collectively our data confirms that FAK activity in the developing myocardium is 
dispensable for anabolic growth of the heart, but is essential for hypertrophic 
progression, supporting previous data in which absence of FAK attenuated the 
hypertrophic response.   
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Generation of the SuperFAK Mouse 
We next examined whether increased FAK activity was sufficient to promote 
hypertrophic growth. To this end, I created a transgenic mouse which expressed 
constitutively active FAK under the control of a shortened 3.2kb piece of the cardiac 
specific βMHC promoter. This modified promoter induced ventricle specific 
expression that, unlike the full length promoter, is not downregulated after birth 
(Figure 3.6, personal communication and [179]).  Constitutive activation of FAK was 
achieved by engineering glutamic acid substitutions for two lysine residues in the 
activation loop of FAK (K578E, K581E) to create a variant termed SuperFAK.  As 
previously described theses mutations increased the catalytic activity of FAK (Figure 
3.5a) [176].  As shown in Figure 3.5b, in comparison to non-transfected cells as well 
as cells transfected with Flag-FAK, FlagSuperFAK induced a significant increase in 
autophosphorylation of FAK as assayed by tyrosine 397 phosphorylation.   
Characterization of the Two βMHCSuperFAK  Transgenic Lines 
We obtained two founder lines that expressed ventricle specific SuperFAK 
protein.  The gene was transmitted in both lines were with Mendelian frequency and 
the founders have survived out to eight months thus far without any noticeable 
morbidity. Following Western analysis of cardiac lysate taken from the two lines 
(SuperFAK 1 and 2) we determined that FAK activity, as assayed by tyrosine 397 
phosphorylation, was increased in both lines compared to wildtype levels of active 
FAK in littermate controls (Figure 3.6). Therefore, to distinguish the expressing lines, 
we named them SuperFAK 1 for the lower expressing line (SF1) and SuperFAK 2 
(SF2) for the higher expressing line. Thus far, both lines have been characterized 
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out to 10 weeks postnatal and the SF1 line has additional data from 16 weeks 
postnatal. We hypothesize that different levels of activated protein in these lines will 
enable us to determine whether there is a dose dependent effect of FAK activity on 
the progression of cardiac hypertrophy. 
Characterization of the SF2 Mouse Line 
 Given the substantial increase in tyrosine 397 observed at four weeks of age 
in the SF2 mice, we hypothesized that the SF2 mice would induce cardiac 
hypertrophy in the absence of a pathological challenge. To date, two groups of SF2 
mice have been examined: an end stage group at four weeks postnatal, and an end 
stage group at ten weeks postnatal. To determine the cardiac specificity of the 
transgene, various tissue lysates from SF2 and littermate control mice were 
compared for expression of flag protein. As expected, flag protein was present 
specifically in the heart and was not observed in skeletal muscle, stomach and aorta 
(Figure 3.7b). To evaluate FAK activity in the SF2 mice at four and ten weeks 
postnatal, cardiac lysates from transgenic and control mice were examined for an 
increase in phospho-397 via Western analysis (Figure 3.7a).  Immunoblot analysis 
revealed an increase in FAK activity in the SF2 hearts relative to control hearts. 
Despite the increased FAK activity, there was no difference in heart weight versus 
body weight measurements or heart weight versus tibia length in the SF2 mice at ten 
weeks postnatal relative to controls (data not shown).   
 To look for hypertrophic cardiac remodeling at the cellular level, SF2 hearts 
were paraffin embedded, sectioned, and examined for any histological changes.  
Both control and SF2 trichrome stained heart sections displayed an increase in 
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fibrosis from four to ten weeks of age. Interestingly, there is a slight increase in the 
degree of vascular fibrosis noted in the SF2 mice likely due to cardiomyocyte 
remodeling (Figure 3.8). In addition, cardiomyocyte cross-sectional area was 
significantly increased in SF2 hearts at ten weeks of age compared to littermate 
controls indicating that at the cellular level, increased FAK activity leads to an 
increased growth response (Figure 3.9).   
 As assayed by quantitative RT-PCR, the SF2 mice exhibited an increase in 
pathological gene expression compared to controls. RNA extracted from ten week 
postnatal SF2 hearts displayed a significant increase in βMHC expression compared 
to control hearts. This pathologic change was also accompanied by an increase in 
ANF and a decrease in αMHC in the SF2 hearts.  The change of the gene 
expression in the heart indicates that these mice are undergoing a pathological 
hypertrophic change significant enough to result in changes in fetal gene expression 
(Figure 3.10).  Although we observed the hypertrophic progression as indicated by 
an increase in cell area and alterations in gene expression, there were no significant 
changes in heart size as assayed by echocardiography at ten weeks postnatal.  
 
Characterization of the SF1 Mouse Line 
 To date, three groups of SF1 mice have been examined: an end stage group 
at four weeks, an end stage group at ten weeks, and a current group at 16 weeks 
postnatal which were analyzed by echocardiography.  Examination of cardiac lysate 
taken at four and ten weeks postnatal showed a significant increase in FAK activity 
via Western analysis similar to the SF2 mice (data not shown). We found that left 
ventricle heart weights at ten and 16 weeks postnatal were increased compared to 
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littermate controls (Figure 3.11c). In accordance with this data, echocardiograph 
measurements completed at this time showed a significant increase in LVPW,d  at 
10 weeks postnatal. At 16 weeks postnatal, there was a significant increase of the 
LVPWs,d and IVS,s in the SF1 mice relative to controls, indicative of a hypertrophic 
response in these animals (Figure 3.11a,b).  In addition, the SF1 mice displayed an 
increase in cardiac function as determined by a significant increase in fractional 
shortening and ejection fraction (Figure 3.11d). Although there was a significant 
increase in LVPW,d at the 10 week time point, this change was not accompanied by 
any pathological genetic changes in ANF or βMHC as assayed by quantitative 
RTPCR.  Gene profiles will be completed at later time points to determine if 
prolonged exposure to low levels of active FAK will indeed induce pathological 
hypertrophy in these mice.  
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D. Discussion 
 FAK is an important regulator of cardiac hypertrophy; however, the critical 
question of whether FAK activity is necessary and sufficient to induce cardiac 
hypertrophy in vivo was heretofore not known.  Herein, we have described two novel 
mouse models which enabled us to explore the consequence of myocardium 
restricted inhibition or overexpression of active FAK during anabolic growth and 
pathologic hypertrophy. The cardiac expression of MycFRNK in the CX1frnkMlc2vCre 
mice resulted in mice that were born with Mendelian frequency and that were 
phenotypically comparable to controls from birth to adulthood. In this model, 
although the presence of FRNK was able to decrease ventricular FAK activity it did 
not affect anabolic growth of the heart nor did it affect baseline cardiac function. 
However, following chronic aortic constriction, decreased FAK activity attenuates the 
hypertrophic response similar to previously published data [33]. Thus, the presence 
of FAK protein, as well as full activation of FAK is critical for mediating the 
pathological hypertrophic response in vivo. Our results from the SuperFAK mice 
suggest that constitutively active FAK is sufficient to induce cardiac hypertrophy in 
the absence of any mechanical stimuli.  These studies demonstrate that FAK 
activation is both necessary and sufficient for the induction of cardiac hypertrophy. 
  The traditional germline deletion of FAK results in embryonic lethality and 
makes studying the effect of FAK activity in heart development and in the 
progression of cardiac disease impossible. Therefore, we generated a MycFRNK 
transgenic mouse that can be crossed with various Cre expressing lines to enable 
us to study the effect of decreased FAK activity from development to adulthood.  In 
 112
our model, Cre recombinase is able to initiate recombination between pairs of loxP 
sites that flank a stop signal in the transgene leading to Cre-mediated expression of 
MycFRNK. This results in FRNK expression days and weeks before we are able to 
see knockout of the FAK protein using the floxed FAK gene with identical Cre mice. 
This is because we do not have to wait for gene abrogation of both floxed alleles and 
subsequent protein degradation [33].  This model additionally allows us to study the 
fundamental difference between FAK expression and activity throughout cardiac 
development and disease. 
 Since FAK is an integral part of the focal adhesion complex which serves to 
connect the ECM to sarcomeres, it is possible that the effects observed in our past 
knock-out models were due to disruptions of this structural complex and not simply 
due to blocking FAK activity.  However, in this current model, although FAK’s kinase 
activity has been dampened due to the presence of FRNK, FAK protein is still 
present and can still serve as a structural scaffold within the cell. Therefore, in 
addition to elucidating a role for FAK activity during anabolic growth of the heart, the 
use of MycFRNK enables us to study the potential role of FAK as a critical 
pathological hypertrophy signal transducer.  
  It is reported that FAK can promote cell growth and proliferation in a variety of 
cell types in vitro [180, 181]. Thus, in our model, it is presumed that increased FAK 
activation would lead to increased cell growth.  Our results from echocardiography 
and cardiomyocyte cross sectional area indicate that FAK is an important signal 
transducer in the cell growth signal cascade regulating the pathological hypertrophic 
response but not anabolic growth. In the SF1 line, echocardiograph measurements 
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revealed the transformation of the heart into a more hypertrophic state. This was 
also supported by increased LV mass in the gender-matched SF1 mice at both ten 
and sixteen weeks postnatal. Additionally, myocyte area measurements in the SF2 
mice demonstrated an increase in overall cell size relative to control cells. However, 
due to non-gender matched controls in the ten week end stage group of the SF2 
mice, heart weight versus body weight measurements did not show an increase in 
cell size.  Future end stage studies at a variety of time points will determine if, in the 
presence of increased active FAK, overall heart weight increases in proportion to 
body weight and whether active FAK induces gene expression changes indicative of 
pathological remodeling.  
A reversion in the gene expression to a fetal gene profile is a hallmark of 
pathological cardiac hypertrophy. At ten weeks postnatal we observed increased 
expression of in ANF and βMHC, and a decreased expression of αMHC in SF2 
hearts. Notably, levels of expression of these genes correlate directly with the extent 
of hypertrophy observed in other mouse models [162]. Collectively, we observed that 
increased FAK activation alters the structural framework and molecular profile of the 
heart, indicative of a hypertrophic response in the absence of hypertrophic stimuli.  
Additional studies will confirm the extent of hypertrophy in both SuperFAK 
lines, as well as any additional structural and functional changes indicative of 
pathological hypertrophy.  Hearts from end stage experiments with gender matched 
controls at a variety of time points throughout adulthood will be examined for 
changes in gene expression, extent of fibrosis and cell size.  In addition to structural 
changes, we will explore through cardiac catheterization any functional changes that 
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are occurring in the heart. Examination of pressure-volume loops from both 
SuperFAK and control hearts will determine if, in the presence of active FAK, the 
SuperFAK hearts have increased contractility and function.  
In addition to proliferation, FAK has also been implicated in cell survival in a 
variety of cell types. Although no increase in apoptosis was found in fak-/- embryos 
or in the cardiac-specific FAK deleted mouse, it is possible that the presence of 
active FAK is protective against apoptotic injury [33, 182]. To examine this 
possibility, we plan on inducing apoptosis by ligating the left anterior descending 
artery of the heart.  Since studies in the MFKO mice revealed a significant increase 
in ischemia-reperfusion infarct size accompanied by an increase in apoptosis we 
hypothesize that the SuperFAK mice will display decreased ischemic injury relative 
to control hearts, indicating that FAK signaling is protective in the heart (unpublished 
observations).  
 Cardiac lysates taken from SuperFAK expressing hearts will be inspected for 
changes in activity and expression of downstream effectors of FAK.  Our previous 
work reported a decrease in ERK activation in the absence of FAK protein following 
adrenergic stimulation [33].  Therefore, it will be interesting to determine whether, in 
the absence of other external stimuli, ERK activation is increased in hearts 
containing increased FAK activation.  Work completed in this thesis showed that 
FAK is important in regulating the hypertrophic response following pathological 
stimuli. However, it is also known that FAK can activate proteins involved in the 
physiological hypertrophic pathway (Figure 3.1). Therefore, other downstream 
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effectors involved in both the pathological and physiological hypertrophic pathway 
will be examined for changes in activation and expression.   
  It is possible that the different levels of active FAK in these hearts is causing 
varying hypertrophic responses. The SF1 mice may require a longer exposure to 
FAK activity to result in the changes in gene expression noted in the SF2 mice. 
Further analyses including echocardiography and examination of changes in fetal 
gene changes in aged mice, histological inspection for increased fibrosis, increased 
cell size and disorganized myocytes will help to determine the timing and extent of 
pathological hypertrophy in these mice. In addition, further characterization of these 
lines will allow us to explore the possibility that moderate levels of FAK activity will 
lead to physiological hypertrophy while dramatically increased levels may result in a 
pathological hypertrophic response. The exploration of specific pathways involved in 
both physiological and pathological signaling and further genetic studies at later 
adult time points will help to elucidate the specific changes that are occurring.   
In summary, our findings highlight an important role for FAK signaling in 
mediating cardiac hypertrophy. Our models which increase or decrease FAK activity 
in the myocardium demonstrated that FAK signaling is both necessary and sufficient 
to induce cardiac hypertrophy and may be a promising target for the treatment of 
heart disease.  
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Figure 3.1. Characterization of the MycFRNK Transgenic Mouse.  a, 
Diagrammatic representation of the CX1frnk transgene. b, Cultured cells were 
transfected with the CX1frnk transgene and infected with an adenovirus driving 
expression of the Cre recombinase. Lysates taken before infection and 24, 48, 72, 
and 96 hours post-infection were processed by SDS-PAGE and probed with anti-
FAK or anti-GFP antibodies. c, Immunoblots of tissue lysates from the CX1frnk 
transgenic mice (tg) and wildtype mice (wt) were probed with anti-GFP, anti-Myc, 
and anti-ERK antibodies. d, Left ventricles from 2 month old CX1frnk mice were 
processed for immunohistochemistry using anti-GFP antibodies. 
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Figure 3.2. Targeted Myocyte Specific Inhibition of Focal Adhesion Kinase. a, 
Illustrative representation of the CX1frnk and Mlc2vcre breeding strategy. b,  
Percentage of mice positive for both CX1frnk and Mlc2vcre at three weeks and one 
year postnatal. c, Ventricle lysate from control (C) and MycFRNK (F) mice were 
separated by SDS-PAGE and probed with anti-FAK antibody. d, Cardiac lysates 
taken from E14.5, E18.0, 1 day, 3 month, 6 month and 9 month CX1frnkMlc2vcre mice 
were separated by SDS-PAGE and probed with anti-FAK antibody to visualize 
MycFRNK. MycFRNK transfected Cos cell lysate shown as positive control. e, 
Western blot analysis of MycFRNK levels in heart, skeletal muscle, and stomach 
from control (C) and MycFRNK (F) expressing mice.  f, Immunoblots of control (C) 
and MycFRNK (F) heart lysate were probed with anti-FAK and anti-phosphotyrosine 
397 antibodies.  
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Figure 3.3. Inhibition of FAK in the Postnatal Heart Does Not Alter Anabolic 
Growth.  a, Left ventricles from two month old CX1frnkMlc2vcre and CX1frnkMlc2vwt/wt 
mice were processed for histology and stained with Masson’s Trichrome to reveal 
myocyte organization and levels of fibrosis (blue). b, Sections of left ventricles from 
two month old CX1frnkMlc2vcre and CX1frnkMlc2vwt/wt mice were stained with an anti-
cardiac troponin T antibody to reveal myofibrillar organization. c, Cross sectional 
cardiomyocyte area from two month old control and CX1frnkMlc2vcre (FRNK) 
myocytes (n=at least 300 cells per condition).  
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Figure 3.4. Cardiac Expression of MycFRNK Attenuates the Hypertrophic 
Response Following Aortic Banding.  a, Heart weight versus body weight ratios at 
baseline and following 14d of aortic constriction in control, CX1frnkMlc2vwt/wt (n=5) 
and FRNK, CX1frnkMlc2vcre mice (n=6) hearts. b, Percent change in cardiac 
dimensions following 14 days of aortic constriction in control, CX1frnkMlc2vwt/wt and 
FRNK, CX1frnkMlc2vcre mice (n= at least 8 mice). *, p<0.05 compared to baseline. c, 
Cardiomyocyte cell area following 8 weeks of aortic constriction. *, p<0.05.  
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Figure 3.5. Construction of SuperFAK. a, A diagrammatic image of FAK showing 
the activation loop of the kinase domain. To create SuperFAK, two lysines (K578, 
K581) were substituted with glutamic acids (E).  Figure modified from [176]. b,  
Cultured cell lysate from cells transfected with flag-FAK or flag-SuperFAK and 
control non-transfected cells (NT) were processed for Western blot analysis and 
probed with anti-FAK, anti-flag, and anti-phospho-397 antibodies.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 126
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 127
 
Figure 3.6. Identification of the Two SuperFAK Transgenic Mouse Lines. a, 
Illustration of the βMHC-flag-SuperFAK transgenie. b, Cardiac lysate from four week 
old SuperFAK 1 (SF1) and four week old SuperFAK 2 (SF2) mice were analyzed by 
Western blot and probed with antibodies for anti-phospho-397 and anti-cortactin.  
Levels of phopho-397 were compared to littermate controls (C) for each line.  
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Figure 3.7. Characterization of the SuperFAK Mouse. a, Cardiac lysate from four 
and ten week old littermate control (C) and  SuperFAK 2 (SF) mice were separated 
via SDS-PAGE and probed with anti-phospho-397,  anti-flag, and anti-ERK 
antibodies. b, Tissue lysates from SuperFAK 2 (SF) heart, skeletal, stomach, and 
aorta were analyzed by Western analysis using anti-flag and anti-ERK antibodies.  
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Figure 3.8. Histological Analysis of SuperFAK Hearts. a. Ventricles from ten 
week old control and SuperFAK 2 (SF2) hearts were processed for histology and 
stained with Masson’s Trichrome to determine myofibrillar organization and collagen 
deposition (blue, visible at higher magnification. Top panel=1x, bottom panel=20x). 
Black arrows indicate areas of significant fibrosis. b. Quantification of fibrosis in 
SuperFAK 2 (SF2) hearts.  Cross sections of Trichrome stained hearts were 
quantitated as follows:  0 = no presence of fibrosis, 1 = 0-15% of vessels contained 
peri-vascular fibrosis, 2 = 15-30% of vessels contained peri-vascular fibrosis, 3 = 30-
45% of vessels contained peri-vascular fibrosis. Values of vascular fibrosis were 
added to score for interstitial fibrosis: 1 = presence of interstitial fibrosis, 2 = 
increased interstitial fibrosis, 3 = very significant amount of interstitial fibrosis.  
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Figure 3.9. Increased FAK Activity Results in increased Cardiomyocyte Cell 
Area. Ventricles from control and SuperFAK 2 (SF2) hearts were processed for 
histology and stained with lectin (bottom panel). Cross-sectional area of control and 
SuperFAK 2 myocytes were analyzed (n=at least 300 cells per condition).  *p<0.05 
for indicated comparison.  
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Figure 3.10. FAK Activity Modulates Hypertrophic Gene Expression. 
Quantitative RT-PCR analysis for ANF, βMHC, and αMHC RNA levels in control and 
SuperFAK 2 (SF) hearts. Data was normalized to 18s RNA and presented as fold 
over values from control mice (n=3 per condition). *p<0.05 versus control.  
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Figure 3.11. Prolonged Exposure to SuperFAK Increases Cardiac Size and 
Function. a, Left ventricular posterior wall (LVPW) thickness in diastole (top) and 
systole (bottom) taken from ten, and 16 week old Control and SuperFAK 1  (SF) 
mice. b, Representative echocardiography from Control and SuperFAK 1 (SF1) mice 
at 10 and 16 weeks postnatal. c, Gender matched control and SuperFAK 1 (SF1) left 
ventricular measurements taken from echocardiography at ten and 16 weeks 
postnatal. d, Percent  fractional shortening (%FS) and percent ejection fraction 
(%EF) from 16 week old SuperFAK 1 (SF1) mice. *,p<0.05 compared to control at 
indicated time points.   
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CHAPTER IV 
FAK ACTIVITY IS REQUIRED FOR PROPER CARDIAC DEVELOPMENT 
A. Introduction 
Recent genetic evidence indicates that the integrin class of fibronectin (FN)-
binding adhesion receptors (α5β1 and others) can regulate the form and function of 
the heart [60, 134, 139, 183-185].  Integrin ligation drives recruitment of a number of 
structural and signaling molecules to the ventral plasma membrane. This complex is 
collectively termed a focal adhesion. These focal adhesions link the force-generating 
actin cytoskeleton inside the cell to the extracellular matrix (ECM), and  coordinate 
activation of downstream signaling pathways [3].  The non-receptor tyrosine kinase, 
Focal Adhesion Kinase (FAK), is strongly activated by both integrins and growth 
factors, and is a likely candidate to mediate downstream signals from these diverse 
pathways during cardiac growth and development [136].  Germline deletion of FAK 
results in mesodermal defects and embryonic lethality between E8.5-10 similar to 
the phenotype observed in both FN-null, and α5-null mice, supporting an important 
role for FAK in mediating integrin dependent processes during development [27, 
139].   In addition, FAK is predominantly expressed in the mesoderm of wildtype 
embryos at embryonic day 8.5 [26].  Indeed, hearts from FAK-
null embryos revealed a lack of separate mesocardial and endocardial layers, 
suggesting that FAK may play a role in cardiac morphogenesis [26].  
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The heart forms from two separate progenitor cell populations or heart fields 
referred to as the primary and secondary heart fields. These fields divide from a 
common progenitor at gastrulation [45-47].  The primary heart field arises from the 
anterior splanchnic mesoderm and is responsible for the formation of the cardiac 
crescent and ultimately the left ventricle and atria [48]. The secondary heart field 
originates from the pharyngeal mesoderm and contributes to the right ventricle and 
outflow tract [45, 46, 49]. The primary heart field is distinguished by expression of 
specific transcription factors Tbx5, bhHLH and Hand2 whereas the secondary heart 
field is mediated by the transcription factor Isl1 and Fgf10 [45, 46].  The homeobox 
gene Nxk2.5 is expressed in both heart fields [50].  
The heart is the first organ to form and is crucial for embryonic viability. A 
significant number of fetal and childhood mortalities can arise from defects in the 
carefully orchestrated steps that govern cardiac development can contribute 
significantly to fetal and childhood mortality [40].  Cardiac organogenesis is initiated 
by the formation of the cardiac crescent by cardiac precursors. Following crescent 
formation, a linear heart tube is formed. The heart tube undergoes a rightward 
looping, giving rise to the ventricular and atrial chambers, thus forming a four 
chambered heart. 
 Genetic studies in drosophila, zebrafish, xenopus, and mice have been 
critical for the understanding of the specific factors required for vertebrate heart 
development [186].  For example, GATA mediates heart tube formation, NF-ATc and 
Smad6 direct the formation of valves, and ErbB2, ErbB4, and neuregulin are 
required for the growth and maturation of cardiomyocytes [58, 59, 187, 188] . 
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Although a basic genetic blueprint of transcription factors for cardiac development is 
known, questions still remain regarding the signaling pathways mediating 
cardiogenesis. Based on past studies involving FAK binding partners and upstream 
activators in cardiac development, we reasoned that FAK signaling is likely an 
important step in the intricate morphogenesis process.  
In order to study a role for FAK in the developing myocardium, we generated 
a transgenic mouse model which enables tissue-specific expression of a dominant 
interfering mutant for FAK termed Focal Adhesion Related Non-Kinase (FRNK), In 
this model, MycFRNK is expressed downstream of a region of the β-actin promoter 
that drives high levels of expression in all tissues and induces conditional expression 
of MycFRNK in the presence of a tissue specific Cre recombinase. Previous in vitro 
experiments demonstrated the effective inhibition of FAK activity with FRNK in 
isolated cardiomyocytes [37].  Therefore, we rationalized that FAK activity is 
necessary for cardiac morphogenesis and used FRNK in vivo to elucidate a role for 
FAK activity in the developing myocardium. To target development, we used the 
Nxk2.5-Cre knock-in mouse line which facilitates robust expression of Cre 
recombinase as early as E7.5 [189].  The recent use of the Nxk2.5-Cre mouse line 
with the floxed FAK mouse revealed peri-natal lethality due to malformations in the 
outflow tract, a sub-aortic ventricular septal defect with overriding aorta or double 
outlet right ventricle. The malformations in the Nkx2.5-Cre driven FAK knockout 
mouse were due to an impaired cardiomyocyte migration [32].  In addition, 
significant protein depletion was not observed in the FAK knockout model until 
E13.5, days after the heart has completed formation.  Unlike this FAK knockout 
 143
model, the MycFRNK transgenic mouse enables more precise control of protein 
expression since the expression of a protein will occur days before homozygous 
gene inactivation and subsequent protein degradation present in a floxed loxP/Cre 
model [32]. Of interest, this model will allow us to note the potential differences in 
decreased FAK activity in these mice compared to previously published deletion of 
FAK protein and enable us to examine the role of FAK as a kinase and as a 
molecular scaffold [32]. We found that decreased FAK activity during cardiac 
development results in embryonic lethality between E14-E15 due to a significant 
cardiomyocyte proliferation defect.  Hearts with Nkx2.5 driven expression of 
MycFRNK resulted in a significant reduction in heart size, and cardiomyocyte 
proliferation accompanied by a ventricular septation defect.   
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B. Material and Methods 
Generation of MycFRNK Mice. A 1.4kb fragment of MycFRNK was amplified out of 
the pRK5mycFRNK vector to incorporate 3’ and 5’ Not1 sites with an internal Kpn 
site[38].  This fragment was then ligated into a vector containing a cassette in which 
a piece of the βactin promoter is fused to cDNA containing GFP flanked by loxP 
sites. Ultimately, the CX1-MycFRNK fragment was cut out using Kpn, linearized, and 
submitted for pronuclear microinjection into 0.5 day fertilized embryos at the UNC 
Animal Models Core Transgenic Facility which was preformed within the University 
of North Carolina at Chapel Hill.  DNA isolated from tail snips or tissues was 
subjected to PCR analysis using primers specific for the MycFRNK transgene (5’-
CGCGGTACCATCCAGACATGATAAGATACATTGATGAG-3’ and 5’-
CGCCTCGAGGCTGCCACCATGGAGCAGAAGCTGATC-3’). Dr. Robert Schwartz 
(Institute of Biotechnology, Houston) provided the Nkx2.5Cre knock-in mice [29, 189].  
Both lines of mice were backcrossed to the C57black6 background at least 6 
generations prior to subsequent breeding. DNA isolated from tail snips or tissues 
was subjected to PCR analysis using primers specific for Cre (5-
ACCCTGACCCAGCCAAAGAC-3’ and 5’-CTAGAGCCTGTTTTGCACGTTC-3’). 
Mice were housed in an AALAC accredited University Animal Care Facility. 
Generation of the SuperFAK Mice. A 3.2 kb Not1 fragment comprising the 
modified βMHC promoter was amplified from a vector and ligated into a pBKS 
plasmid [32]. SuperFAK was amplified from a pBKS plasmid and cloned into a flag 
vector with BamHI and XhoI sites using standard procedure [176]. FlagSuperFAK 
was subsequently cut from the flag vector using NotI and SpeI to place it 
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downstream of the βMHC promoter in the pBKS plasmid.  Pronuclear microinjection 
of the linearized βMHCflagSuperFAK plasmid into 0.5 day fertilized embryos was 
performed at the UNC Animal Models Core Transgenic Facility at the University of 
North Carolina at Chapel Hill. Transgene expression in C57/Bl6 X C3H hybrid strain 
founders and F1 progeny mice were confirmed by PCR analysis using primers 
specific for the SuperFAK transgene (5’-CCGGCATGGAGATGCTACTG-3’, and 5’-
GCGGCCGCAAGCTGCCACCATGGACTACAAGG-3’).  Six founder mice tested 
positive for the βMHCflagSuperFAK transgene. However, of these six, two 
expressed the flag-SuperFAK protein in the heart.  These lines were breed with 
black6 mice and F1 progeny characterized. All transgenic mouse procedures were 
performed in accordance with the guidelines set forth by the Institutional Animal 
Care and Use Committee (IACUC). 
Western Blotting. Tissues were lysed in modified radioimmune precipitation assay 
buffer (50 mM Hepes, 0.15 M NaCl, 2 mM EDTA, 0.1% Nonidet -40, 0.05% sodium 
deoxycholate, pH7.2) containing 1 mM 4-(2-amnionethyl)benzenesulfonyl fluoride 
hydroxychloride, 0.02 mg/ml aprotonin containing 5% Triton-X. Proteins were boiled 
in a sample buffer and resolved using SDS-PAGE and transferred to nitrocellulose. 
Western blots were performed using a 1:1000 dilution of the appropriate primary 
antibody.  Blots were washed in Tris-buffered saline, pH 7.4 plus 0.05% Triton-X, 
followed by incubation with either horseradish peroxidase-conjugated protein A-
Sepharose (Amersham Bioscience) or horseradish peroxidase-conjugated rabbit 
anti-mouse antibody (Amersham Biosciences) at a 1:2000 dilution. Blots were 
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visualized after incubation with chemiluminescence reagents (ECL, Amersham 
Biosciences). [155].  
Histological Analysis and Immunohistochemistry. Paraffin-embedded hearts 
were sectioned into 8 μm slices and stained with hematoxylin and eosin (Sigma-
Aldrich) to assess overall morphology. Cell area measurements were conducted on 
TRITC-Lectin (Sigma-Aldrich) stained cross sections of the compact zone of the 
heart muscle using Image J software (NIH).   
Antibodies and Reagents. The FAK, ERK2 (1B3B9) and cortactin (4F11) 
antibodies were purchased from Upstate Biotechnology, Inc. The caspase-3 
antibody was purchased from Cell Signaling. The phosphospecific Pky2 antibody 
was purchased from BioSource International and total Pyk2 antibody was purchased 
from BD transduction laboratories. Unless specified, antibodies were used at a 
1:1000 dilution.  
Quantitative RT-PCR.  Hearts were harvested from E13.5 embryos, pooled in 
groups of 3 based on genotype, homogenized, and RNA was extracted using Trizol 
reagent (Invitrogen). Each sample of RNA was diluted to 50 ng/μl in DEPC treated 
H20. Each 30 μl RNA reaction mixture contained 0.5 μl of 0.1 μg/μl of primer, 1 μl of 
20 μmol of probe, 15μl of AB Gene one step master mix, and 0.1μl of RT enzyme.  
The primers and probes used were as follows: βactin forward 
CTGCCTGACGGCCAAGTC, βactin reverse CAAGAAGGAAGGCTGGAAAAGA, 
βactin probe FAM-CACTATTGGCAACGAGCGGTTCCG-TAMARA. c-Fos forward 
CAGTCAGAGAAGGCAAGGCA, c-fos reverse TCCTCTCTGTAATGCACCAG, c-
Fos probe FAM-CATCCAGACGTGCCACTGCCCGA-TAMARA. The real time-RT-
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PCR was performed using the ABI prism 7500 Sequence Detection System (PE 
Applied Biosystems) in 96-well plates under the following conditions:  30 minutes at 
48 ˚C, 10 minutes at 95 ˚C, 40 cycles of 95 ˚C for 15 seconds, then 60 ˚C for one 
min. 
 For semi-quantitative RT-PCR analysis, each 20μl reaction contained 250ng 
of cardiac RNA from end stage mice, 4μl reaction mix and 1μl reverse transcriptase 
using the iScript cDNA synthesis kit (BioRad). Each reaction was performed under 
the following conditions: 5 minutes at 25 ºC, 30 minutes at 42 ºC, then 5 minutes at 
85 ºC.  Each 50 μl PCR reaction mixture contained 2.5 μl of 10μM of primer, 4μl of 
dNTP mixture, 5μl of reaction buffer and 0.5 μl of TaKaRa Ex Taq enzyme. The 
reaction was performed under the following conditions: 5 minutes at 94 ºC, 29 cycles 
of one minute at 94 ºC, one minute at 61 ºC, 2 minutes at 72 ºC, and a final 
extension of 10 minutes at 72 ºC. The primers used were as follows:  Bax forward 
GCGTCCACCAAGAAGCTGAG, Bax reverse ACCACC CTGGTCTTGGATCC, Bcl-2 
forward TGTGGCCTTCTTTGAGTTCG, Bcl-2 reverse 
TCACTTGTGGCCCAGGTATG. 
Apoptosis and Cell Proliferation Assays. Apoptosis was assessed on paraffin-
embedded tissue sections using a DNA fragmentation detection kit, FragELTM DNA 
(Calbiochem) according to the manufacturer’s protocol. Cardiac cell proliferation was 
determined by BrdU labeling which was achieved by administering 100 mg/Kg of 
BrdU (Sigma) to pregnant mice intraperitoneally. Embryos were harvested 3-4 hours 
later, fixed, and embedded in paraffin. BrdU incorporation was detected by 
immunohistochemistry using a commercially available kit (Zymed). Apoptosis and 
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cell proliferation were quantified by scoring the number of FragEL- and BrdU-positive 
nuclei in the muscular IVS per unit area using NIH Image J software.  
Statistics.  Data are presented as mean ± SEM. Means were compared by 2-tailed 
Student’s t test. p<0.05 was considered statistically significant. 
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C. Results 
FRNK Protein is Not Detectible in the Developing or Postnatal Heart  
Previous studies suggest that FAK was highly expressed in mesodermal 
tissues throughout embryonic development. Therefore, we examined FAK 
expression in the heart and found that high levels of FAK were observed from E10.5 
to postnatal day 7.  These time points correlate with the window of cardiomyocyte 
proliferation. We also examined whether FRNK might be expressed since several 
smooth muscle specific genes are transiently expressed in the embryonic heart.  
Detection of FAK and FRNK from aortic SMC lysate and various heart lysate was 
examined using a C-terminal anti-FAK antibody that recognizes both proteins.  
Although FAK is expressed in high levels during development and in lower levels in 
the adult heart, FRNK is undetectable at all stages of heart development and limited 
to the SMC lysate (Figure 4.1).  
Nkx2.5 Targeted Expression of FRNK 
 Since FRNK is not expressed in the heart, we utilized our CX1frnk transgenic 
mouse line in combination with the Nkx2.5-Cre knock-in mouse line to study the 
effect of FAK activity in early stages of heart development (Figure 4.2a).  The CX1frnk 
mouse was created following successful inhibition of FAK activity with FRNK in vitro 
[38]. The CX1frnk mouse was designed such that the MycFRNK gene is driven by a 
region of the β-actin promoter that induces high expression in all tissues. However, 
a GFP reporter followed by a transcriptional stop site has been inserted upstream of 
the transgene, thus preventing expression of MycFRNK.  Importantly, the GFP-stop 
codon region is flanked as a unit by loxP sites, which direct Cre recombinase-
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mediated excision (Figure 4.2a).  Thus, the CX1-stop-MycFRNK-transgenic mice 
can be crossed with a second line of mice that express the Cre recombinase under 
the control of a cell or tissue specific promoter to render specific MycFRNK 
expression and subsequent decreased FAK activity.  A detailed characterization of 
the CX1frnk transgenic mouse can be found in Chapter III. In this study, we crossed 
the CX1frnk with the Nxk2.5-Cre promoter since this is a robust promoter that turns 
on around mid-gestation (E7.5) and has a fairly broad expression pattern. Unlike the 
Mlc2v-Cre mouse utilized in Chapter II and III, the Nkx2.5-cre recombination is 
induced in the primary and secondary heart fields and in the epithelium and 
endothelium of the first pharyngeal arch [189].   
Histological and Morphological Analysis of CX1frnkNkx2.5cre Mice 
 Viable offspring expressing both the CX1frnk and Nkx2.5cre transgenes were not 
detected and subsequent studies revealed that CX1frnkNkx2.5cre mice died between 
embryonic day 14.5 and 15.5 (Figure 4.2b). By embryonic day E14.5, 
CX1frnkNkx2.5cre embryos showed a significant increase in overall edema, potentially 
due to cardiac failure in these animals (Figure 4.2c).  Western analysis of embryonic 
hearts from CX1frnkNkx2.5cre mice showed the presence of MycFRNK in the 
myocardium as early as E10.5 and continued high expression at E12.5 and E13.5 
(Figure 4.2d, data not shown). The expression of MycFRNK occurs shortly after the 
onset of FAK expression in the embryo.  In wildtype embryos, FAK expression 
gradually increased from E8.0 onward in all tissues, although expression was most 
predominant in the mesoderm at midgestation (E8.5) [26]. Therefore, expression of 
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MycFRNK in the CX1frnkNkx2.5cre embryos should be able to inhibit FAK activity 
shortly after it is expressed in the embryo.  
  Histological examination of coronal sections through the CX1frnkNkx2.5cre 
hearts revealed similar heart size and ventricular wall thickness at E10.5.  In 
addition, we found similar morphologies of the endocardial cushion relative to 
genetic controls. However, as development progressed from E10.5 to E13.5, the 
ventricular walls expanded in the control hearts and the interventricular septum (IVS) 
grew and fused with the outflow tract (OFT) in the control hearts while little growth 
was observed in the CX1frnkNkx2.5cre hearts (Figure 4.3). Cardiac sections from 
E14.5 CX1frnkNkx2.5cre embryos revealed a significant reduction in ventricular wall 
size compared to controls as well as endocardial cushion defects resulting in 
malformation of the bicuspid and tricuspid valves. Histological analysis of E14.5 
coronal heart sections revealed a 48% reduction in overall ventricular cellular area in 
the CX1frnkNkx2.5cre hearts compared to aged matched controls (Figure 4.4).  
 We also examined non-cardiac tissues known to express Nkx2.5 for any 
defects [189].  CX1frnkNkx2.5cre embryos at embryonic day 14.5 revealed normal 
craniofacial development and no indication of cleft palate (Figure 4.2, data not 
shown). In addition, there were no overall histological differences observed in the 
tongue, spleen, and thymus compared to genetic controls at E13.5 (tongue) or E14.5 
(spleen, thymus) (Figure 4.5).  
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MycFRNK Expression Results in Decreased Cell Proliferation but Does Not 
Affect  Apoptosis 
 As previously indicated, FAK can regulate a variety of biological processes. In 
some cell types, activation of FAK has been shown to be important for cell survival, 
and inhibiting FAK activity can lead to apoptosis [12, 24, 25].  We examined E13.5 
MycFRNK hearts for increased DNA fragmentation at the cellular level and for 
increased apoptotic markers.  Although hearts with decreased FAK activity displayed 
a significant reduction in ventricular mass, this phenotype was not attributed to 
increased apoptosis. Figure 4.6a shows a similar percentage of TUNEL positive 
cells in both control and MycFRNK hearts.  We also examined cleaved caspase-3, 
since the presence of its cleaved 12 and 17kDa subunits associate to form an active 
enzyme and are key indicators of apoptosis [190].  Cardiac lysate from both control 
and MycFRNK hearts showed similar levels of the uncleaved 32 kDa caspase-3 
while the cleaved 17 and 12 kDa pieces were undetected by immunoblot (Figure 
4.6b). In addition, we examined RNA for increased expression of genes important in 
pro-apoptotic pathways such as Bax or a decrease in genes involved the pro-
survival pathway involving Bcl-2.  In accordance with the previous data, there was 
no change in Bax or Bcl-2 expression as detected by semi-quantitative RT-PCR 
(Figure 4.6c).  Overall, our data suggest that the cardiac phenotype associated with 
the MycFRNK hearts is not due to an increase in apoptosis.    
 Data from the fak-/- mouse revealed that FAK may regulate cell proliferation in 
some cell types [26]. Therefore, we examined cell proliferation in the MycFRNK 
hearts to determine if the significantly smaller heart size was due to a proliferation 
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defect. Following maternal BrdU injection, we noted that there was significantly less 
BrdU incorporation in the hearts containing MycFRNK relative to control hearts 
indicative of a proliferation defect (Figure 4.7a).  These data were supported by 
quantitative RT-PCR data from E13.5 MycFRNK and control hearts that showed a 
significant decrease in cardiac cFos expression, an early immediate gene involved in 
cell growth (Figure 4.7b). In summary, the expression of MycFRNK in the heart does 
not increase apoptosis, but does result in a proliferation defect.  
Embryonic Lethality is Due to a Cardiomyocyte Specific Growth Defect  
 Since Nkx2.5 is not limited to the primary heart field, it is possible that the 
myocyte proliferation defect observed in the MycFRNK hearts is due to aberrant 
growth signals from surrounding non-myocyte NXK2.5 expressing cells derived from 
the secondary heart field and in the endocardium and endocardial cushions [189].  
To determine if the defects observed in CX1frnkNkx2.5cre were due to a 
cardiomyocyte autonomous effect we bred the Nkx2.5cre mice with a novel mouse 
model that expresses constitutively active FAK, termed SuperFAK, under the control 
of the heart-specific βMHC promoter. The βMHC promoter is activated between E7.5 
and 8 and is restricted to ventricular cardiomyocytes by E10 [191]. A detailed 
characterization of the SuperFAK mouse is available in Chapter III. For these studies 
we used the SuperFAK 1 line of mice. The resultant βMHCSuperFAKNkx2.5cre mouse 
was then crossed with the MycFRNK transgenic to create a mouse that expresses 
MycFRNK in Nkx2.5 expressing cells and active FAK in the cardiomyocytes (Figure 
4.8a).  The resultant mice, termed SuperFAK rescue mice (SFR), were born with no 
gross morphological phenotype at neonatal day 1. The pups were sacrificed at day 2 
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postnatal and we examined their hearts for gross and microscopic morphological 
abnormalities. Although viable, gross examination of the heart revealed an abnormal 
shape with apparent dilated left and right ventricles (Figure 4.8b, top panel). 
Interestingly, the SFR mice demonstrated a substantial, although not complete, 
reversal of the proliferation defect and ventricular septation defect noted in the 
CX1frnkNkx2.5cre embryos (Figure 4.8b, bottom panel). In addition, bicuspid and 
tricuspid valve formation in the SFR hearts was similar to control sections (data not 
shown).  High power images reveal that there was still a left ventricular compaction 
defect in the SFR hearts (Figure 4.9). Taken together, these data confirm that FRNK 
acts as a specific dominant negative to block FAK activity and that FAK activity is 
necessary for cardiomyocyte proliferation during development.  
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D. Discussion 
 The germline deletion of FAK results in embryonic lethality, precluding an 
assessment of the requirement of FAK throughout heart development. We recently 
published that deletion of FAK in Nkx2.5 expressing cells causes significant deletion 
of FAK protein at E13.5. FAK deletion in late gestation results in peri-natal lethality 
due to a profound ventricular septal defect due to a cardiomyocyte migration defect 
[32].  Herein to examine earlier time points in cardiac morphogenesis, we generated 
a MycFRNK transgenic mouse line that was crossed with a heart specific Cre 
expressing line to enable us to study the effect of decreased FAK activity in the heart 
during development. This model results in expression of FRNK, the dominant 
negative of FAK, days before we are able to see reduction of the FAK protein using 
the Nxk2.5-floxed FAK model. This is because we do not have to wait for Cre-
mediated recombination of both floxed alleles and subsequent protein degradation of 
FAK (which has a relatively long half-life, 24hrs), allowing us to examine the role of 
FAK at different points in development [32].  
 Since the Nkx2.5 promoter is capable of inducing higher expression of Cre at 
an earlier stage of development than the Mlc2v promoter, it is not surprising that we 
observe a vastly different phenotype compared to the CX1frnkMlc2vcre model 
(Chapter III). Briefly, the CX1frnkMlc2vcre mouse showed ventricular specific 
expression of MycFRNK at postnatal day 1. This expression of MycFRNK, and 
subsequent decrease of FAK activity, was dispensable for proper anabolic growth, 
but was required for pressure-overload induced pathological cardiac hypertrophy. 
Unlike the CX1frnkMlc2vcre model, we see robust expression of MycFRNK at E10.5 in 
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the CX1frnkNxk2.5cre embryonic hearts. At this point in development, the hearts have 
undergone looping and formation of trabeculae along the inner myocardial layer, 
near the curvature of the primitive ventricle [192]. Additionally, the superior and 
inferior cushions in the AV canal have formed by epithelial to mesenchymal 
transformation (EMT) [193]. Also at this time (E10.5), epicardial cells invade the 
myocardium and may play a role in myocardial maturation [194]. At the E10.5 stage, 
CX1frnkNxk2.5cre mice have similar histology compared to their littermate controls. At 
E12.5-13.5 the cushions fuse to form the valve primordia, the ventricular septum 
fuses, and there is proliferation of the compact myocardial layer and continuing 
formation of trabeculae [195].  It is during these changes that we observe a 
proliferation and ventricular and atrial septation defect in the CX1frnkNxk2.5cre mice. 
These defects become more pronounced at E14.5 when there is subsequent 
compaction of the left ventricle. This coincides with invasion of the developing 
coronary vasculature from the epicardium in the control embryos [196].  This 
significant decrease in proliferation in the CX1frnkNxk2.5cre hearts is supported by the 
overall decrease in cellular area and considerable decrease in cFos expression.  
 Endogenous wildtype FRNK is expressed primarily in SMCs and functions as a 
dominant negative of FAK. Although we have yet to show definitively by Western 
analysis that FAK activity is decreased in the CX1frnkNkx2.5cre hearts, we are 
confident that the expression of MycFRNK in these mice is inhibiting FAK activity.  
Numerous western blots were unable to determine differences in levels of active 
FAK in the MycFRNK containing hearts compared to controls. It is possible that 
there is a significant decrease FAK activity in the Nxk2.5 expressing cells, but the 
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high levels of FAK activity in cardiac fibroblasts during development are masking this 
signal.  Previous work by our lab showed that overexpressing FRNK in SMCs by 
adenoviral infection of these cells with GFP-FRNK inhibited autophosphorylation of 
FAK on tyrosine 397, as well as the Src-dependent phosphorylation sites in FAK-
pY556, pY557, and pY861 [37, 155].  In addition, data in Chapter III of this thesis 
supported that in vivo expression of MycFRNK in the myocardium was also able to 
inhibit autophosphorylation of FAK (Figure 3.3f). However, because we were unable 
to definitively show that FRNK was functioning as an inhibitor of FAK activity in the 
CX1frnkNkx2.5cre hearts and that the proliferation defect was not a secondary effect 
to exogenous expression of MycFRNK, we crossed the CX1frnkNkx2.5cre mice with 
the SuperFAK mouse.  The SuperFAK mouse contained cardiomyocyte specific 
constitutively active FAK under the control of the βMHC promoter. The use of these 
mice demonstrated that the CX1frnkNkx2.5cre hearts had a decreased level of FAK 
activity causing the cardiac phenotype. 
       The MycFRNK model also allows us to study the fundamental difference 
between FAK expression and activity throughout cardiac development. Our recently 
published paper addressing deletion of FAK using the Nkx2.5-floxed FAK mouse 
(termed, FAKnk mouse) showed a significantly different phenotype than the 
CX1frnkNkx2.5cre embryos. In the FAKnk animals, the mice died shortly after birth due 
to a profound sub-aortic ventricular septal defect and associated mal-alignment of 
the outflow tract [32]. Unlike the MycFRNK model, the FAKnk hearts revealed no 
significant difference in proliferation. This is possibly due to a time dependent 
requirement for FAK activity on proliferation during midgestation, but not late 
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gestation. Notably, inhibiting FGFR signaling with adenoviral dominant-negative 
mutants of FGFR1 or with translation of endogenous FGFR1 antisense RNA during 
the first week of chicken embryonic development inhibited myocyte proliferation 
and/or survival [197]. However, the inhibition of FGFR1 during the second week of 
embryonic development had much less effect on myocyte growth suggesting that 
proliferation and survival are FGF dependent in early cardiac development, but 
myocyte growth in later stages of development is FGF-independent [197]. 
Interestingly, the FAKnk model also shows no difference in apoptosis relative to 
controls, indicating that FAK expression and FAK activity are not essential for cell 
survival during cardiac development.  
  The use of constitutively active FAK was able to alleviate the cardiac 
phenotype in the MycFRNK mouse but was not able to completely rescue the 
phenotype.  This is most likely due to the amount of SuperFAK expression 
compared to MycFRNK expression.  The SuperFAK mouse we used in these 
experiments was the lower expressing line, SuperFAK1 (see Chapter III). Therefore 
it is likely that there is sufficient FAK activity to improve cardiomyocyte proliferation, 
but no enough to reverse it. It will be of interest to examine the rescue effects of the 
higher expressing SuperFAK line, SuperFAK 2, to determine if increased FAK 
activity will completely rescue the phenotype. Additionally, the expression of βMHC 
driven SuperFAK is limited to ventricular cardiomyocytes whereas Nkx2.5 drives 
expression of FRNK in myocyte and non-myocyte cells. Therefore the resultant 
phenotype may be due to a combination of abnormalities in the non-myocyte cells 
that express FRNK but not SuperFAK. Further studies need to be completed 
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including the examination of SuperFAK expression during development as well as 
the ratio of SuperFAK to FRNK expression at this time.  
Several studies have examined the expression and activity of Pyk2 in models 
of FAK deletion or inhibition. Previous in vitro work with fak-/- fibroblasts indicated 
that in the absence of FAK, expression and activation of Pyk2 are elevated [157].  
However, overexpression of FRNK in cultured cardiomyocytes inhibited Pyk2 
phosphorylation [198].  Interestingly, our recent in vivo work showed comparable 
Pyk2 protein levels (and activity) in control and MFKO hearts (Chapter II) as well as 
in the FAKnk hearts indicating that Pyk2 does not compensate for loss of FAK in 
these models [32, 33]. Therefore, given the differential results from in vitro studies 
with FAK deletion or inhibition as well as the differential results between the in vitro 
and in vivo experiments, it will be of interest to examine the levels of Pyk2 
expression and activity in the CX1frnkNkx2.5cre hearts. If Pyk2 expression and/or 
activity is altered in these mice, it will also be of interest to examine the rescue 
hearts to determine if the presence of SuperFAK would reverse this change.  
 In summary, our findings highlight the importance of FAK activity in the 
developing myocardium.  Further studies involving the SuperFAK mouse, including 
those proposed in Chapter III of this thesis will help to elucidate the specific 
functions of FAK activity in adult cardiomyocytes. Increased FAK activity in the adult 
myocardium may result in increased proliferation of cardiomyocytes which suggests 
that FAK may be a potential therapeutic target for heart disease. 
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Figure 4.1.  Expression of FAK and FRNK During Heart Development. Hearts 
were isolated from embryos or mice at various time points as indicated. Cardiac and 
smooth muscle cell (SMC) extracts were analyzed by SDS-PAGE and 
immunoblotted using anti-FAK antibody to detect both FAK and FRNK, and anti-
tubulin antibody.  FAK is expressed in high levels during development and low levels 
in the adult heart, while FRNK is undetectable at all stages of heart development.  
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Figure 4.2. Generation of CX1frnkNkx2.5cre Mice. a, CX1frnk transgenic mice were 
bred with Nkx2.5-Cre knock-in mice to produce progenies with or without cardiac 
expression of MycFRNK. b, Number of progeny that were positive for the MycFRNK 
transgene and for Cre over total number of progeny. c, Gross morphological 
analysis of control and FRNK embryos taken at E14.5. d, Western analysis of  E13.5 
cardiac lysate from control (C) and MycFRNK (F) hearts using anti-FAK and anti-
ERK antibodies.  
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Figure 4.3. Histological Analysis of CX1frnkNkx2.5cre Mice.  Histological analysis 
of hematoxylin and eosin stained coronal heart sections from E10.5, E12.5 and 
E13.5 from control CX1wtNxk2.5cre hearts and CX1frnkNxk2.5cre MycFRNK expressing 
hearts.  
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Figure 4.4. Decreased FAK Activity in CX1frnkNxk2.5cre Hearts Results in a 
Cardiomyocyte Proliferation Defect.  a, Control CX1wtNxk2.5cre hearts and 
CX1frnkNxk2.5cre MycFRNK at E14.5 are stained with hematoxylin and eosin to 
observe any histological differences in the ventricular walls of the hearts at 2x, 10x, 
and 40x. b, Cellular area measured in Control and MycFRNK hearts at E14.5. 
*p<0.05 versus control.  
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Figure 4.5. Comparable Histology in Other Tissues with Nkx2.5 Expressing 
Cells.  Hematoxylin and eosin stained spleen (E14.5,100x), thymus (E14.5, 40x) 
and tongue (E13.5, 10x) sections from control and CX1frnkNxk2.5cre embryos.  
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Figure 4.6.  Inhibition of FAK Activity Does Not Increase Apoptosis. a, 
Quantification of FragEL stained apoptotic cells of the ventricles in control and 
MycFRNK expressing hearts at E13.5. b, Western analysis of total and cleaved 
caspase 3 levels in genetic control (C) and MycFRNK (F) hearts at E13.5. c, RNA 
from pools of 3 hearts each from genetic controls and MycFRNK expressing E13.5 
hearts were examined for expression of Bax and Bcl-2 by RT-PCR. Control samples 
consist of MycFRNK transgene only (F), Nxk2.5-Cre only (C), and wildtype (W) 
samples. Densitometry quantification of Bax compared to Bcl-2 (right panel).  
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Figure 4.7.  Decreased FAK Activity Inhibits Cellular Proliferation. a, 
Quantification of ventricular BrdU incorporation in E13.5 control and FRNK embryos. 
*p,<0.05. b, Quantitative RT-PCR analysis of RNA from E13.5 hearts examined for 
expression of c-Fos. Data is represented as fold over control β-actin expression. 
*p,<0.05. 
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Figure 4.8. Generation of SuperFAK Rescue Mice. a, Breeding strategy  to create 
SuperFAK rescue mouse. First cross involves breeding the SuperFAK mouse with 
the Nkx2.5-Cre mouse. Progeny that are positive for Cre and the SuperFAK 
transgene are then bred with the Cx1frnk mouse. b, Gross morphological comparison 
of control (CX1frnk) and SuperFAK rescue (SFR) hearts at day 2 postnatal (top 
panel). Paraffin embedded sections of control and SFR hearts were stained with 
hematoxylin and eosin (bottom panel).  
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Figure 4.9. SuperFAK Alleviates Proliferation and Ventricular Septation Defect. 
High powered images show histological analysis of hematoxylin and eosin stained 
control (CX1frnk) and SuperFAK rescued left ventricles.  
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Chapter V 
OVERALL DISSCUSSION AND FUTURE DIRECTION 
Germline deletion of FAK results in early embryonic lethality, making it difficult 
to study the specific role for FAK in cardiac development and disease.  We have 
overcome this hurdle by creating various mouse lines which express FAK, or its 
dominant negative FRNK, in a tissue specific manner.  We used these mice to 
explore the role of FAK in heart development, anabolic growth, and cardiac disease. 
Collectively, the use of these conditional mouse models revealed that FAK activity 
and/or expression is required for cardiomyocyte proliferation during development, is 
dispensable for anabolic growth of the heart, and is necessary and sufficient for the 
induction of cardiac hypertrophy.  
As noted above, germline deletion of FAK is embryonic lethal between E8.5 
and E10. The mesodermal defect resulting from the loss of FAK protein suggests 
that FAK may be important in cardiac development. In addition FN, the major 
activator of FAK,  as well as FAK binding partners including p130Cas and paxillin, 
have been implicated in heart development [61-63].  To show that FAK activates 
critical pathways required for normal development and function of the heart, we 
induced cardiac field-specific FRNK expression, and subsequent inhibition of FAK 
activity, in Nkx2.5-Cre expressing cells. 
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 Expression of FRNK in Nxk2.5-Cre expressing cells resulted in a more 
dramatic phenotype than we observed following FAK depletion using the same Cre 
line. Indeed, the conditional expression of FRNK in the heart field caused embryonic 
lethality between E14-E15, while the FAK deleted model, (termed FAKnk)  mice died 
postnatally [32].  FRNK expression resulted in a significant reduction in 
cardiomyocyte proliferation, atrial and ventricular septal defects, and malformations 
of the bicuspid and tricuspid valves. However, FAKnk mice demonstrated 
malformations in the outflow tract that manifested as a profound sub-aortic 
ventricular septal defect with overriding aorta or double outlet right ventricle that 
resulted in defective blood oxygenation and peri-natal lethality [32]. The 
malformations noted in the FAKnk mice were due to impaired cardiomyocyte 
migration. The differential phenotypes between the FAKnk mouse and the current 
FRNK overexpressing model are most easily explained by the precise timing of the 
ablation of FAK protein and activity in the two models. The Nxk2.5 promoter drives 
Cre recombinase expression in cardiac progenitors at E7.5 and has been reported to 
induce recombination as early as E9 in cardiomyocytes [189]. However, due to a 
combination of inaccessibility of FAK alleles and a long FAK half-life, FAK protein in 
the FAKnk mouse was not reduced until E13.5, days after the onset of FRNK 
expression at E10.5. Thus, by the time FAK protein was depleted in the FAKnk 
hearts, these hearts has already undergone a robust proliferation burst and 
compaction of the ventricles [32].  Collectively, our studies reveal that FAK activity 
regulates cardiomyocyte proliferation during mid-gestation whereas FAK controls 
cardiomyocyte migration in late gestation. 
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The use of the novel heart specific constitutively active FAK model, 
SuperFAK, allowed us to determine if the phenotype observed in the 
CX1frnkNkx2.5cre hearts was a cardiomyocyte autonomous effect or due to decreased 
FAK activity in non-myocyte Nxk2.5-cre expressing cells. Initial data from the 
SuperFAK rescue mouse revealed that increased FAK activity in cardiomyocytes 
was able to alleviate the proliferation defect and ventricular septal defect in the 
CX1frnkNkx2.5cre hearts. These initial data proved especially interesting since 
activation of FAK in otherwise slow dividing or non-dividing cells was able to initiate 
proliferation, the key to reversing heart disease.  
Due to the small number of SuperFAK rescue mice analyzed at this time, a 
variety of experiments will need to be completed to fully characterize the observed 
phenotype. Additional mice at postnatal day 1 will be sacrificed and their hearts 
examined for general morphology as well as histological differences in ventricular 
wall thickness, myofibrillar organization, deposition of ECM fibrosis, and cell size.  
SuperFAK rescue mice will also be monitored at various postnatal time points to 
examine any morbidity and mortality that may occur following extended stress on the 
heart. Protein lysates will be isolated from embryonic day 14.5 as well as postnatal 
day 1 hearts to determine the ratio of active FAK to FRNK. In addition, a variety of 
downstream effectors of FAK may be altered,  including ERK, PI3K and AKT due to 
their role in cardiomyocyte growth [85, 199]. Lastly, to examine cellular proliferation 
in the SuperFAK rescue mice, embryonic hearts will be assessed at E14.5 following 
maternal BrdU exposure. These data will help to identify the specific pathways that 
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are altered in these mice and will confirm whether increased FAK activity is able to 
improve cardiomyocyte proliferation. 
 Although FAK activity was required for proper cardiac development in both 
the CX1frnkMlc2vcre and MFKO models, where FAK is deleted or inhibited postnatal, 
FAK was dispensable for basal myocyte function. Both models showed similar heart 
morphology, histology, and function compared to controls at baseline. Although FAK 
resides with cytoskeletal proteins in the Z-disk, it is not an integral part of the 
contractile apparatus and may function primarily as an effector for integrin signaling. 
In wildtype embryos, FAK expression gradually increases from E8.0 onward and is 
ubiquitously expressed, although expression is most predominant in the mesoderm 
at midgestation (E8.5) [26]. This expression remains high throughout development, 
and then decreases postnatally into adulthood (Figure 4.1). Because of its 
comparably low levels in the adult heart, FAK signaling may not play a pivotal role in 
heart structure or function of the heart during adulthood.  
 Although FAK activity was dispensable for anabolic growth in the 
CX1frnkMlc2vcre mice, data from the MFKO mice suggest that FAK protein plays a 
role in heart growth during aging. The heart is exposed to higher levels of IGF-1 and 
growth factor during anabolic growth than it is in the aged heart, and diminished 
levels of these hormones combined with deletion of FAK from the myocardium, may 
result in the significantly smaller MFKO hearts seen at 14 months of age. In addition, 
it is possible that the inhibition or deletion of FAK results in an impaired growth 
response, but this difference is not apparent until 14 months of age.  Lastly, the 
differential downstream signals governing FAK deletion versus decreased FAK 
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activity may manifest in an impaired growth response during aging. To further 
elucidate these differences, a group of MycFRNK mice will need to be examined at 
14 months of age for decreased heart size and cell size relative to littermate 
controls.  
 Previous work by our group and others indicate that FAK is important for the 
hypertrophic response. We have described three novel mouse models (MFKO, 
CX1frnkMlc2vcre, and SuperFAK) that collectively support the idea that FAK signaling 
is necessary and sufficient for the progression of cardiac hypertrophy. Following 
biomechanical or adrenergic stimuli, activation of FAK results in the activation of the 
ERK and JNK growth promoting MAP kinases and the cytoskeleton-regulating small 
GTPases Rac and Rho, some of the same molecules implicated in myocyte 
hypertrophy [131, 136].   We showed that inhibition of FAK activity and deletion of 
FAK inhibits the progression of hypertrophy in vivo.  Data from the MFKO mice 
suggest that ERK activation may be the primary mechanism for the blunted 
hypertrophic response.   
Conditional activation of FAK stimulated the progression of cardiac 
hypertrophy in the absence of biomechanical stress. Since ERK signaling mediates 
cell growth and given that the MEK1-ERK1 signaling precedes the induction of 
hypertrophic gene expression in vivo, it is possible that activated FAK enhances the 
ERK-1/2 signaling pathway in the SuperFAK hearts. In addition to further 
characterizing the hypertrophic response present in these mice, we plan to examine 
the altered signaling pathways downstream of FAK that contribute to the 
hypertrophic phenotype.  
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            In conclusion, the examination of a role for cardiac FAK from mid-gestation 
to aged adult highlights the importance of FAK in development and disease.  These 
studies assessed the different biological functions of FAK in the myocardium, 
illustrating the importance of FAK in promoting proliferation during cardiac 
development and in promoting myocyte hypertrophy in the adult heart.  Therefore, 
targeting FAK activity may be a promising avenue for the treatment of heart disease. 
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